

REVIEW ARTICLE

# ADAM-17: the enzyme that does it all

Monika Gooz

Department of Medicine, Medical University of South Carolina, Charleston, SC, USA

## Abstract

This review focuses on the role of ADAM-17 in disease. Since its debut as the tumor necrosis factor converting enzyme (TACE), ADAM-17 has been reported to be an indispensable regulator of almost every cellular event from proliferation to migration. The central role of ADAM-17 in cell regulation is rooted in its diverse array of substrates: cytokines, growth factors, and their receptors as well as adhesion molecules are activated or inactivated by their cleavage with ADAM-17. It is therefore not surprising that ADAM-17 is implicated in numerous human diseases including cancer, heart disease, diabetes, rheumatoid arthritis, kidney fibrosis, Alzheimer's disease, and is a promising target for future treatments. The specific role of ADAM-17 in the pathophysiology of these diseases is very complex and depends on the cellular context. To exploit the therapeutic potential of ADAM-17, it is important to understand how its activity is regulated and how specific organs and cells can be targeted to inactivate or activate the enzyme.

**Keywords:** Ectodomain shedding; growth factor; inflammation; signalling; proteolysis; TNF $\alpha$

## Introduction

ADAM enzymes (*a* disintegrin and metalloproteinase) are Zn<sup>2+</sup>-dependent, modular cell surface proteins which belong to the adamalysin protein family. They are closely related to other metalloenzymes such as ADAM-TSs (ADAMs with thrombospondin domains), matrix metalloproteinases (MMPs) and snake venom metalloproteinases (SVMP). The structure of ADAMs closely resembles the Class III snake venom metalloenzymes or reprotolysins (discussed in detail in Calvete *et al.*, 2007) and it forms the basis of the many ADAM enzyme functions. The typical ADAM modules and their comparison to modules present in MMP and SVMP are depicted in Figure 1.

ADAMs can have both adhesive and proteolytic properties and can therefore participate in cellular adhesion and proteolytic cleavage of various cell surface molecules. Therefore, ADAMs are also important mediators of cell signaling events which determine cellular fate, proliferation, and growth (Blobel, 2005; Edwards *et al.*, 2008). Because of these features, ADAMs are important contributors to physiological and pathophysiological processes and may be potential therapeutic targets in

various diseases. In the mammalian genome 40 ADAMs were identified, and in the human genome 21 ADAMs have been described. However, of these 21 molecules, only 13 are proteolytically active (Edwards *et al.*, 2008). Some ADAMs lose their metalloenzyme domain during intracellular maturation and some lack the necessary Zn-binding (HEXXHXXGXXH) sequences present in their catalytic domain to be proteolytically active (ADAM-1-7, 22, 23, 29, 31, 32). These proteolytically inactive ADAMs participate in intercellular communication through their adhesive properties rather than by activating cell surface molecules through proteolytic cleavage or "shedding".

Some ADAM enzymes can be expressed in somatic cells and some are present primarily in the testis, which suggests tissue-specific function (reviewed in detail in Edwards *et al.*, 2008). The importance of ADAMs is underscored by the fact that orthologs of some of the most vital ADAM genes (ADAM-10 and -17) can be found in yeast *Schizosaccharomyces pombe* (Nakamura *et al.*, 2004), in *Drosophila melanogaster*, and in primitive chordates such as *Ciona intestinalis* and the zebrafish *Danio rerio* (Huxley-Jones *et al.*, 2007).

Our review focuses on ADAM-17, one of the most well studied ADAM enzymes. However, there are several


*Address for Correspondence:* Monika Gooz, 96 Jonathan Lucas Street CSB Suite 829, Division of Nephrology/Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA. Tel: 843 789 6771. E-mail: beckm@musc.edu

(Received 02 December 2009; revised 12 January 2010; accepted 15 January 2010)

ISSN 1040-9238 print/ISSN 1549-7798 online © 2010 Informa UK Ltd  
DOI: 10.3109/10409231003628015

<http://www.informahealthcare.com/bmg>

RIGHTS LINK  
Copyright Clearance Center



**Figure 1.** Comparison of ADAM modules to modules present in SVMPs and MMPs.

excellent recent reviews available which discuss the importance and roles of other ADAMs (Blobel, 2005; Higashiyama and Nanba, 2005; Huovila *et al.*, 2005; Charrier-Hisamuddin *et al.*, 2008; Edwards *et al.*, 2008; Reiss and Saftig, 2009).

### ADAM-17 makes history

ADAM-17 was discovered in 1997 and described simultaneously by two research groups as the enzyme that releases membrane-bound tumor necrosis factor (TNF)- $\alpha$  precursor to a soluble form (Black *et al.*, 1997; Moss *et al.*, 1997b). This discovery was significant because TNF $\alpha$  is critical in inflammatory processes (Feldmann *et al.*, 1995), and there had been a lengthy search to identify the enzyme responsible for solubilizing this cytokine. Investigators hypothesized that the sheddase enzyme that cleaves cell-surface-bound pro-TNF $\alpha$  was a metalloenzyme because hydroxamate-type inhibitors attenuated surface-bound pro-TNF $\alpha$  release from cells (Mohler *et al.*, 1993; 1994; McGeehan *et al.*, 1994). However, the discovery that this cytokine-releasing enzyme belongs to the adamalysins provided the first evidence for physiological catalytic activity of ADAMs (Black *et al.*, 1997; Moss *et al.*, 1997b) as previously ADAMs were merely regarded as adhesion molecules.

ADAM-17 (synonyms: CD156b; cSVP; MGC71942; tumor necrosis factor converting enzyme (TACE)) was described as a protein of 824 amino acids (accession number NM\_003183), and its gene is located on chromosome 2p25. ADAM-17 is widely expressed in various tissues including the brain, heart, kidney, and skeletal muscle, and its expression changes during embryonic development and adult life (Black *et al.*, 1997). ADAM-17 is a multi-domain protein starting with a signal sequence (1–17 aa), followed by a prodomain (18–214 aa), a metalloenzyme or catalytic domain (215–473 aa) with the typical HEXXHXXGXXH (X being any amino-acid

residue) sequence, a disintegrin domain (474–572 aa), an a cysteine-rich domain (603–671 aa), followed by a transmembrane domain (672–694 aa) and a cytoplasmic tail (695–824 aa). ADAM-17 has very little sequence similarities with other ADAMs (see phylogenetic review in Edwards *et al.*, 2008); its closest relative is ADAM-10 (NM\_001110.2); however, their protein sequence homology is less than 30% according to NCBI Blast.

### Function of ADAM-17

#### *Protein ectodomain shedding and its functional consequences*

The most well-known function of catalytically active ADAMs, including ADAM-17, is to cleave ectodomains of various transmembrane proteins. The proteolysis usually occurs at the membrane-adjacent part of the molecule. Proteins with different function can be processed by ectodomain shedding: epidermal growth factor receptor (EGFR) ligands, proinflammatory cytokines such as TNF $\alpha$  and its receptor TNFR1, adhesion molecules and the amyloid precursor protein (Black *et al.*, 1997; Moss *et al.*, 1997b; Peschon *et al.*, 1998; Lammich *et al.*, 1999; Reddy *et al.*, 2000; Garton *et al.*, 2003). ADAM-17 has preferences for certain proteins as discussed below, but catalytically active ADAMs can have overlapping substrate “specificity” (for lists of known ADAM substrates see the recent review by Edwards *et al.* (2008)). After cleavage, the molecules can bind to their receptor on the same cell (autocrine effect), or can bind to receptors on neighboring cells. Alternatively, they can reach more distant cells in the same tissue (juxtacrine and paracrine effect) and even enter the bloodstream (endocrine effect) (Wiley *et al.*, 1998; Borrell-Pages *et al.*, 2003). Usually, the Golgi apparatus provides a reserve for the shedded ligand, and ligand shedding can mobilize ligand movement to the membrane (Wang, J. *et al.*, 2003).


Protein cleavage can regulate cellular signaling and affect cell behavior, but the result always depends on the cellular context. Because both substrate and receptor can be cleaved, several scenarios are possible. The cleaved substrate can bind to its receptor and then the activated receptor initiates downstream signaling events: ADAM-17 can cleave heparin-binding epidermal growth factor (HB-EGF) which, in turn, activates EGFR and initiates cell proliferation (Gooz, M. *et al.*, 2006) (Figure 2A). However, the receptor can be cleaved from the cell surface; thus, ectodomain shedding can actually stop the ligand-initiated signaling: ADAM-17-induced macrophage colony-stimulating factor receptor cleavage downregulates activated macrophages (Rovida *et al.*, 2001) (Figure 2B). Failure in receptor downregulation and normal turnover can have serious consequences as observed in TNF-receptor associated periodic febrile syndrome (TRAPS) (McDermott *et al.*, 1999). A mutation in the cleavage site of the TNF receptor I can lead to receptor accumulation on the cell surface due to inefficient shedding. Receptor abundance increases cell susceptibility to TNF $\alpha$  and TRAPS patients have increased inflammatory responses with concomitant fever (Figure 2C). If the receptor shedding occurs before the ligand binding, the receptor can serve as a decoy and inhibit the ligand binding to cell surface receptors. For example, breast cancer cells that overexpress Her-2 escaped anti-Her-2 antibody-mediated inhibition of cell proliferation by shedding large amounts of soluble Her-2, which captured the antibody prior to it reaching cells (Brodowicz *et al.*, 1997) (Figure 2D).

Interestingly, activation of membrane-bound receptors (for example EGFR) by EGFR ligand binding can result in either cell proliferation or apoptosis, depending on which other signaling pathways are activated or “connected” to the host-receptors pathway (Jackson *et al.*,

2003; Blobel, 2005). Therefore, inhibiting or knocking down a receptor which activates *inhibitory* signaling pathways can actually activate the previously inhibited processes. An example of this mechanism is the contribution of EGFR activation to normal heart development via the Smad/Bone Morphogenic Protein (BMP) signaling pathway. EGFR activates Smad signaling, thereby *inhibiting* hyperproliferation of cells in developing heart valves (Kretzschmar *et al.*, 1997). Also, Smad6 $^{-/-}$  mice were confirmed to have enlarged heart valves (Galvin *et al.*, 2000), and EGFR knockout mice and HB-EGF $^{-/-}$  mice develop hyperplastic heart valves (Chen, B. *et al.*, 2000; Jackson *et al.*, 2003). Insufficient or inactive EGFR during heart valve development therefore hinders activation of an inhibitory mechanism (Smad) and leads to *activation* of a proliferative pathway.

### Regulated intramembrane proteolysis (RIP)

What then happens with the cleaved intramembrane/cytoplasmic part of the proteins is presently unclear. However, the transmembrane module of certain proteins has been shown to be further processed by regulated intramembrane proteolysis or RIP (Schroeter *et al.*, 1998; De Strooper *et al.*, 1999; Wolfe *et al.*, 1999). Signaling through Notch, a protein involved in cell-fate decisions, involves cleavage of the Notch receptor first on its ectodomain by ADAM-10 or ADAM-17 at a so-called  $\alpha$ -position (Brou *et al.*, 2000), which is followed by a second intramembrane cleavage by multi-protein protease complex  $\gamma$ -secretase, which includes enzymes like presenilin (Hartmann *et al.*, 2001; Six *et al.*, 2003). The intracellular domain of Notch is transferred to the nucleus where it regulates transcription of various genes (Lewis, 1998). Another example is the processing of the  $\beta$ -amyloid precursor protein (APP), which is responsible for amyloid plaque formation in Alzheimer's disease (Masters *et al.*, 1985). APP is cleaved first by ADAM-17 or ADAM-10 and, similar to Notch, the remaining molecule is processed by presenilin (Buxbaum *et al.*, 1998). The intracellular fragment induces intracellular Ca $^{2+}$  signaling (Leissring *et al.*, 2002). This process results in a soluble extracellular fragment that does not contribute to amyloid plaque formation (Anderson *et al.*, 1992; Kojro and Fahrenholz, 2005). In contrast, decreased activity or lack of  $\alpha$ -secretases allows  $\beta$ -secretase to cleave the extracellular module of APP at a more distal region which will result in formation of the amyloidogenic  $\beta$  peptide (Yan *et al.*, 1999). Furthermore, recent investigations provided evidence that after ectodomain shedding the EGFR ligands HB-EGF and neuregulin are proteolytically cleaved on their C-terminal domain and signal to the nucleus (Nanba *et al.*, 2003; Bao *et al.*, 2003). Therefore, other than soluble factor-induced events, backwards signaling could provide cellular feedback and



**Figure 2.** Consequences of protein ectodomain shedding. (A) Cleaved substrate binds to its receptor and initiates downstream signaling events. (B) Receptor cleavage stops ligand-initiated signaling. (C) Failure to downregulate receptor hypersensitizes the cells for receptor agonist. (D) Shedded receptor serves as decoy for antibody and contributes to resistance in cancer.

could mobilize transport of additional factors to the cell surface. The consequences of this “backwards signaling” require further investigations. Also, it would be interesting to know whether all transmembrane proteins for which the ectodomain is processed undergo transmembrane proteolysis.

### Inter-receptor crosstalk


Ectodomain shedding is an important element of communication among different types of cell surface receptors. Crosstalk between G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs) was first reported in 1999 (Prenzel *et al.*, 1999). The mechanism which involved GPCR-induced activation of a matrix metalloenzyme and subsequent shedding of the EGFR ligand heparin-binding EGF (HB-EGF) was the archetype of “triple-membrane spanning signaling”. Prenzel showed that activation of several distinct GPCRs can induce phosphorylation of the EGFR through the same ligand: HB-EGF. Since then, several other EGFR ligands have been identified in inter-receptor crosstalk, including EGF, amphiregulin, neu-regulin 1-4, epiregulin, epigen, TGF $\alpha$  and betacellulin. ADAM-10, -12, -15 and -17 were documented as growth factor shedding enzymes (for a recent review see Edwards *et al.*, 2008). GPCR agonists implicated in inter-receptor crosstalk that utilizes ADAM-17 include angiotensin-II (Lautrette *et al.*, 2005), ATP (Yin and Yu, 2009), lysophosphatidic acid (LPA) and thrombin (Gschwind *et al.*, 2003), membrane type bile acid receptor (M-BAR)/TGR5 (Yasuda *et al.*, 2007), endothelin-1 (Sanderson *et al.*, 2006), carbachol (Alfa Cisse *et al.*, 2007), and serotonin (Gooz, M. *et al.*,

2006). It is important to note that the same GPCR agonists can induce cleavage of various substrates depending on the cell type (and probably the cellular context). Thus, angiotensin-II is implicated in ADAM-17-mediated TGF $\alpha$  shedding of kidney cells (Lautrette *et al.*, 2005), in HB-EGF shedding of ACHN kidney carcinoma cells (Schafer *et al.*, 2004) and in HB-EGF shedding of vascular smooth muscle cells (Ohtsu *et al.*, 2006). In contrast, the same ligand can be involved in different pathophysiological processes mediated by ADAM-17. Thus, the enzyme can shed amphiregulin both in lung (Lemjabbar *et al.*, 2003), and in colon cancer cells (Merchant *et al.*, 2005). Another regulatory *checkpoint* of the GPCR-RTK crosstalk which can add variability to the signaling process is that, *upon activation*, EGFR monomers can form not only homodimers but also heterodimers. This process involves engagement of other ErbB family members, such as the ErbB4 receptor, which can add additional variability to the outcome of the signaling process as heterodimers have different substrate preferences than the EGFR homodimer (Murali *et al.*, 1996; Citri *et al.*, 2003; Li, Z. *et al.*, 2007) (Figure 3).

### Regulation of ADAM-17

#### ADAM-17 domains and their role in regulating ADAM-17 enzymatic activity

The *prodomain* of ADAM-17 serves as the initial inhibitor of the enzyme during its translation (Gonzales *et al.*, 2004; Li, X. *et al.*, 2009). Interestingly, there is evidence that its function is enhanced by the presence of the disintegrin



**Figure 3.** Substrate binding of EGFR/ErbB heterodimers.



domain of the enzyme (Gonzales *et al.*, 2004). The prodomain of ADAM-17 is cleaved by furin, a pro-protein convertase, in the trans-Golgi network (Schlondorff *et al.*, 2000) at the last four amino acids (Arg-Val-Lys-Arg) preceding the catalytic domain. Interestingly, in contrast to other MMPs, the cysteine switch mechanism – the binding of Cys184 to the Zn<sup>2+</sup> ion in the catalytic domain's active center – does not appear to be the mechanism of auto-inhibition in the case of ADAM-17. Prodomain variants containing a Cys184A mutation are still capable of inhibiting the enzyme activity (Leonard *et al.*, 2005). Recently, the key inhibitory sequence was identified as Phe72 and the Asp-Asp-Val-Ile137 motif (Gonzales *et al.*, 2008). In contrast, others have described a 19-amino-acid, leucine-rich domain, corresponding to ADAM-17 amino acids 30–48 (Buckley *et al.*, 2005), which inhibited ADAM-17-mediated TNF receptor 2 (TNFR2) cleavage, independent of the cysteine switch mechanism. Cleaved pro-domains can form a complex with the mature form of the ADAM enzyme in some instances (Fahrenholz *et al.*, 2000; Wewer *et al.*, 2006; Moss *et al.*, 2007); however, for ADAM-17, we have no reports concerning the possible interaction between mature ADAM-17 and its processed prodomain. Immunohistochemical studies suggest that most of the active form of ADAM-17 is localized in the cellular perinuclear region, with a small amount present in the plasma membrane (Schlondorff *et al.*, 2000). It was also shown that removal of the prodomain is not necessary for ADAM-17 transport to the cell surface, as during pro-protein convertase inhibition, an immature form of ADAM-17 was present in the plasma membrane (Peiretti *et al.*, 2003a). There is evidence that ADAM-17 is “packaged” into lipid rafts during its transport and maturation through the Golgi apparatus, and that this spatial distribution also contributes to ADAM-17 activity regulation by keeping the enzyme separated from its substrates (Tellier *et al.*, 2006).

The *catalytic domain* or metalloenzyme domain of ADAM-17 contains the classical Zn<sup>2+</sup> chelating sequence HEXXHXXGXXH (X being any amino acid residue) and is responsible for processing membrane-bound proteins such as TNF $\alpha$ . ADAM-17 and its closest relative, ADAM-10, have overlapping substrate specificity as well as substrates unique to each. A recent investigation underscored the differences in substrate recognition of these enzymes using peptide library screening and systematic analysis of amino acids next to the cleavage site, and these experiments showed that ADAM-17 prefers smaller aliphatic residues at the P'1 position and that ADAM-10 prefers larger residues, such as leucine (Caescu *et al.*, 2009). The active centers of the enzymes were also compared in mutational studies, and the residues responsible for differences in substrate recognition were found to be present in the S'1 pocket of the enzymes. Also, Val440 was reported to be sufficient and necessary

for ADAM-17 substrate specificity (Caescu *et al.*, 2009). The classical cleavage sequence in TNF $\alpha$  was identified as Ala 76/Val 77 (-Arg-Ser-Ser-Ser) (Kriegler *et al.*, 1988). Analysis of growth hormone receptor (GHR) proteolysis by ADAM-17 revealed that the cleavage site is eight residues from the cell membrane in the extracellular domain of GHR (Wang, X. *et al.*, 2002). It was suggested that the sequence of the substrate cleavage site is less important than its position; the so called “stalk region” between the transmembrane and the first globular part of the molecule determines whether ADAM-17 can cleave the protein (Schlondorff and Blobel, 1999; Wang, X. *et al.*, 2002; Hinkle *et al.*, 2004). However, a recent thorough analysis of an ADAM-17 peptide substrate library showed that the substrate sequence is indeed important (Lambert *et al.*, 2005).

Tissue inhibitors of metalloproteinases-3 (TIMP-3), a native inhibitor of ADAM-17, binds to the ADAM-17 catalytic domain (Amour *et al.*, 1998). However, the effectiveness of this inhibition is greatly influenced by the C-terminal modules of ADAM-17 (disintegrin and cysteine-rich domains), which significantly weaken the inhibitory activity of TIMP-3 (Lee *et al.*, 2002). Studies of the crystal structure of the TIMP-3/ADAM-17 catalytic domain complex revealed that during interaction, TIMP-3 extends into a unique hydrophobic pocket of the ADAM-17 surface, which, together with two leucine residues, allows effective and unique binding of TIMP-3 to the enzyme (Wisniewska *et al.*, 2008). Mutational analyses (M435I, C225Y, C600Y) identified amino acids indispensable for the catalytic activity of ADAM-17 both in the metalloproteinase domain and also in the disintegrin domain (Li, X. and Fan, 2004). The importance of methionine 435 (the so-called met-turn, which gives the metzincin enzyme family its name) in the active site of ADAM-17 was further investigated using M435I, M435L, and M435S mutational constructs (Perez *et al.*, 2007). In contrast to another metzincin enzyme, MMP-2, M453 seems to be necessary for ADAM-17 cleavage of transmembrane growth factors (Perez *et al.*, 2007). The important role of distal ADAM-17 modules in regulating the catalytic domain activity was further confirmed by elegant stopped-flow x-ray spectroscopy methods and transient kinetic analyses which showed that the Zn<sup>2+</sup> ion in the catalytic domain undergoes charge transitions *before* the substrate binds to the metal ion (Solomon *et al.*, 2007). This phenomenon was possibly due to interaction of the substrate with ADAM-17 modules other than the catalytic domain, which underwent conformational changes, triggering change in the catalytic domain. The redox state of two highly conserved cysteinyl sulfhydryl groups (cystein-X-X-cystein) in the disintegrin domain of ADAM-17 also have important roles in regulating ADAM-17 activity, as evidenced by their role in L-selectin secretion in macrophages (Wang, Y. *et al.*, 2009).

*Integrins* are heterodimeric ( $\alpha\beta$ ) transmembrane glycoproteins best known as adhesion receptors mediating cell-cell and cell-matrix interactions (for a review see Giancotti and Ruoslahti, 1999). At present, there are 18  $\alpha$  and eight  $\beta$  integrin subunits identified, which can assemble in 24 different ways. The subunit assembly determines the integrin's substrate specificity; although several integrins can bind to the same type of matrix molecules (Giancotti and Ruoslahti, 1999). Integrins are involved in other cellular processes than adhesion: they participate in outside-in and inside out signaling, cell cytoskeleton reorganization, cell adhesion, migration, cell survival, and proliferation (Giancotti and Ruoslahti, 1999; Huveneers *et al.*, 2007). The *disintegrin domain* of ADAM-17, like other ADAMs, was always regarded as an integrin-binding module, based on its similarity to snake venom disintegrins which are known to competitively inhibit integrin function. Disintegrins are small molecules (20–100 amino acids) which originate from Class II–IV snake hemorrhagic metalloproteinases (SVMP) by proteolytic or autoproteolytic cleavage (Kini and Evans, 1992). Class I SVMPs have only MMP domains, and consequently have the weakest anticoagulant activity among the snake venom metalloproteinases. Disintegrins were first discovered in viper venom based on their ability to inhibit platelet aggregation by interfering with platelet integrin  $\alpha_{IIb}\beta_3$  receptor binding to fibrinogen (Huang *et al.*, 1987). Later, snake venom disintegrins were actually found to interact with a wide range of integrins ( $\alpha_2\beta_1$ ,  $\alpha_4\beta_1$ ,  $\alpha_4\beta_7$ ,  $\alpha_9\beta_1$ ,  $\alpha_v\beta_3$ ,  $\alpha_v\beta_5$ , and  $\alpha_5\beta_1$ ) (Tselepis *et al.*, 1997; Danen *et al.*, 1998; Marcinkiewicz *et al.*, 1999; Zhou *et al.*, 2000; Cominetti *et al.*, 2003), and thereby to affect the cellular function not only of platelets but also of endothelial cells (Olfa *et al.*, 2005), rat mesangial cells (Tsai, T.J. *et al.*, 1995), fibroblasts (Yeh *et al.*, 2001), osteoclasts (Mercer *et al.*, 1998), and tumor cells such as human melanoma cells (Tripathi *et al.*, 1994), lung tumor cells (Galan *et al.*, 2008), and gliomas (Schmitmeier *et al.*, 2003). The integrin-binding affinity of snake venom disintegrins greatly depends on their active-loop sequence for which position is defined by the specific alignment of cysteines (reviewed in detail in Calvete *et al.*, 2003). Most of the Class II SVMPs belong to the Arg-Gly-Asp (RGD)-containing disintegrins, and these, together with “modified RGD”-containing disintegrins (Lys-Asp-Gly, Met-Val-Asp, Met-Gly-Asp, Lys-Gly-Asp, Trp-Gly-Asp), are under intense investigation for therapeutic use in circulation diseases, rheumatoid arthritis, cancer, osteoporosis, and Alzheimer's disease by targeting not only  $\alpha_{IIb}\beta_3$  and  $\alpha_v\beta_3$ , but also the fibronectin receptor  $\alpha_5\beta_1$  integrin (Mercer *et al.*, 1998; Chung *et al.*, 2003). The other group of disintegrins includes members of the non-RGD-containing disintegrins, or MLD- and KTS-disintegrins, which bind mainly to  $\alpha_4\beta_1$ ,  $\alpha_4\beta_7$  and  $\alpha_9\beta_1$

integrins, and  $\alpha_1\beta_1$  integrin, respectively (reviewed in Calvete, 2005; Marcinkiewicz, 2005). These disintegrins are a recent discovery, so further studies are warranted to understand their function.

The disintegrin or disintegrin-like domain of ADAMs resembles the class III SVMPs. However, only ADAM-15 has an RGD sequence in its substrate recognition loop. ADAM-9 has a KTS sequence and many ADAMs have the XCD (usually ECD) motif in their loop sequence. Overall, ADAM disintegrin domains are much larger and more degenerate than snake venom disintegrins (Bridges and Bowditch, 2005). ADAM-17 has an ECD sequence, but it has a tyrosine (Y) in the fifth position whereas all other ADAMs have a cysteine residue. Nonetheless, there is evidence that ADAMs do interact with integrins *even if the exact binding loops have not been well characterized*. For example ADAM-15 was shown to interact with both  $\alpha_v\beta_3$  and  $\alpha_5\beta_1$  (Nath *et al.*, 1999), and ADAM-2, 3, 7, 12, 28 and 33 are capable of both  $\alpha_4\beta_1$  and  $\alpha_9\beta_1$  binding (reviewed in Arribas *et al.*, 2006). However, at this time, the only integrin which was shown to associate with ADAM-17 is integrin  $\alpha_5\beta_1$  (Bax *et al.*, 2004) and there is evidence that ADAM-17 inhibits  $\alpha_5\beta_1$  integrin-mediated cell migration. It was also shown that ADAM-17 does not influence  $\alpha_4\beta_1$  integrin-mediated cell migration, possibly because it cannot bind to this integrin (Huang, J. *et al.*, 2005).

It is important to emphasize that, to date, ADAM/integrin interactions have been studied mostly in the context of cell-cell interactions and cell-matrix interactions or adhesion (Eto *et al.*, 2000; Kawaguchi *et al.*, 2003) and very often with recombinant disintegrin domains “glued” to plastic surfaces, which is essentially studying the molecule out of context. Thus, these investigations provide limited understanding about *in vivo* ADAM/integrin binding. Even if recombinant ADAM-17 was reported to bind purified  $\alpha_5\beta_1$  integrin, and the two proteins co-localized in migrating HeLa cells (Bax *et al.*, 2004), *the physiological significance of these interactions is unclear*. Most importantly, we have no data to show whether  $\alpha_5\beta_1$  integrin binding affects ADAM-17 activity and, consequently, ADAM-17-mediated signaling pathways, and we do not fully understand the meaning of ADAM-integrin interactions. For catalytically inactive ADAMs, disintegrin binding to cell surface integrins can mediate cellular adhesion both of the same cell and of the neighboring cells. Disintegrin-integrin engagement can have other consequences as well: ligation of integrins can initiate important signaling cascades through activation of growth factor receptors, GPCRs, ion channels, and cytokine receptors (Giancotti and Ruoslahti, 1999). Intracellular molecules can cluster at and phosphorylate integrins and influence cell shape and cell behavior, such as migration, growth, and apoptosis. This could be true for the catalytically active ADAMs as well. By binding to integrins *on neighboring*

cells, ADAM enzymes can initiate the above-mentioned signaling cascade and simultaneously influence cell attachment. ADAMs binding to integrins *on the same cell* can influence host cell attachment and initiate signaling cascades. In contrast, disintegrin binding to integrin can signal “backwards” and may influence ADAM activity as disintegrin domains have regulatory role on the catalytic module (Smith *et al.*, 2002; Li, X. and Fan, 2004). Thus integrin binding could modulate disintegrin–catalytic domain interaction. Theoretically, integrin–ADAM binding can have both inhibitory and stimulatory effect on ADAM catalytic activity through inducing conformational change or by regulating spatial, intramembrane distribution of the enzyme and its substrate. Through conformational change, integrins can sequester ADAM, so it cannot access its substrate. Also, integrins can bind ADAM substrate, as was shown for HB-EGF and  $\alpha 3\beta 1$  integrin (Nakamura *et al.*, 1995) and could make it available for the enzyme on the same cell or on neighboring cells, thus promoting ADAM enzyme function. Interestingly, some evidence suggests that integrins can use different activation states when binding to ADAMs versus extracellular matrix molecules (Chen, MS *et al.*, 1999).

The *cytoplasmic domain* of ADAM-17 is a proline-rich, short, 130-amino-acid module. It contains a potential tyrosine phosphorylation site, DKKLDKQYESL, proximal to the transmembrane domain and a Src-homology 3 domain (SH3) binding site (731–738) (UniProtKB/SwissProt), PAPQTPGR (Black *et al.*, 1997). The cytoplasmic domain was suggested to have important signaling function and a potential role in ADAM-17 trafficking was proposed (Soond *et al.*, 2005). However, our data on ADAM-17 trafficking are sparse. Overexpression studies using truncated forms of ADAM-17 showed that the enzyme must be expressed with its transmembrane domain to effectively cleave TNF $\alpha$  when the cells are stimulated with phorbol ester (Reddy *et al.*, 2000). There is evidence that the cytoplasmic domain was *not* necessary for phorbol ester-induced ADAM-17 shedding activity (Reddy *et al.*, 2000; Doedens *et al.*, 2003). Phorbol esters are strong inducers of metalloenzyme activity and are useful tools for studying ADAM activity changes. But the question still remains whether more physiological stimuli would require the cytoplasmic module for a complete cellular response. It was shown recently that ADAM-10 undergoes regulated intramembrane proteolysis by presenilin after its ectodomain was shed by ADAM-9 or -15 (Toussey *et al.*, 2009). The cytoplasmic domain of ADAM-10 then translocates to the nucleus to gene loci undergoing transcription. Because ADAM-10 is the closest relative of ADAM-17, there is a high possibility (and it is tempting to speculate) that the cytoplasmic domain of ADAM-17 itself can undergo RIP and participate in gene transcription regulation.

### Post-translational modification of the enzyme

One of the most important post-translational modifications of ADAM-17 is its pro-domain removal in the trans-Golgi network as described above, a process which results in the mature form of the enzyme. Other important post-translational modifications include glycosylation and phosphorylation of the enzyme. There are six potential N-linked glycosylation sites on the mature form of ADAM-17: three are located on the metalloenzyme module, two are located on the disintegrin module, and one is present on the cysteine-rich domain. There are three further potential N-glycosylation sites on the prodomain, which suggests that glycosylation can be an important regulator of ADAM-17 activity. Indeed, ADAM-17 has been shown to be N-glycosylated (Peiretti *et al.*, 2003a) and it is usually referred to as the 130 kDa form of the enzyme. However, we have no data to show how glycosylation of ADAM-17 affects the activity and/or transport of the enzyme.

Another important post-translational modification of the enzyme is its phosphorylation. The cytoplasmic domain, particularly phosphorylation of its serine and threonine residues, has been studied extensively. However, the data so far are very contradictory. Phorbol ester (PMA) and EGF treatments induced ADAM-17 phosphorylation on *threonine* 735 by mitogen activated protein kinase ERK in transfected CHO cells and HEK293 cells with concomitant increases in cleavage of the transmembrane TrkA neurotrophin receptor (Diaz-Rodriguez *et al.*, 2002). In contrast, others showed that PMA and EGF induced *not threonine (or tyrosine) but serine* 819 phosphorylation of ADAM-17 by ERK (Fan *et al.*, 2003). The authors also showed that ADAM-17 undergoes Ser 791 *dephosphorylation* during growth factor stimulation. However, there are few data regarding non-PMA-mediated phosphorylation of ADAM-17. Zhang and colleagues have shown that the GPCR agonist, gastrin releasing peptide, induces activation of Src-PI3K (phosphoinositid 3-kinase)-PDK1 (phosphoinositide-dependent kinase) in cancer cells (Zhang *et al.*, 2006). They identified PDK1 as the enzyme that directly phosphorylates ADAM-17 *both on threonine and serine* residues. However, the exact phosphorylation sites of or the role of the cytoplasmic tail were not studied. Another GPCR agonist carbachol induced *threonine* 735 and *tyrosine* 702 phosphorylation of ADAM-17 in HEK 293 cells acting on muscarinic M1 and M3 receptors. Wounding, ATP- or LPA-treatment of corneal epithelial cells induced ERK-dependent ADAM-17 *serine* phosphorylation through GPCR-activation (Yin and Yu, 2009). The contradictory data presented by these papers may be due to the fact that investigators used artificial systems: transformed or transfected cells with overexpressed ADAM-17 and mainly PMA to study ADAM-17 phosphorylation. But



it is also possible that ADAM-17 is phosphorylated on different residues depending on the cell type and stimulus. To better understand this phenomenon, more investigation is needed to study ADAM-17 post-translational modification in primary, untransfected cells and using more physiologically relevant stimuli instead of PMA.

### ADAM-17 binding partners

Besides TIMP-3, which is the naturally occurring inhibitor of ADAM-17 binding to the enzyme active center, and integrin  $\alpha 5 \beta 1$ , which binds to the disintegrin/cystein rich domain (Bax *et al.*, 2004), various substrates of the enzyme (discussed below), and several other molecules were identified as binding partners and potential regulatory proteins by yeast two-hybrid screening and co-immunoprecipitation studies. Mitotic arrest deficient 2 (MAD 2) was shown to interact with ADAM-17 cytoplasmic domain (Nelson *et al.*, 1999). The PDZ-domain (post synaptic density protein [PSD95]/Drosophila disc large tumor suppressor [DlgA], and Zonula occludens-1 protein [zo-1]) of protein tyrosine phosphatase-1H was shown to bind also to ADAM-17 cytoplasmic domain (Zheng, Y. *et al.*, 2002). Yeast two-hybrid assay and colocalization studies showed that SAP9 (synapse associated protein-9) interacts through its PDZ3 domain with the extreme C-terminal of ADAM-17, and overexpression of SAP9 inhibited substrate cleavage (TNFRI, TNFR2 and TNF $\alpha$ ) of the enzyme (Peiretti *et al.*, 2003b). Interestingly, others showed that SAP9 can interact with the cytoplasmic domain of both ADAM-17 and its ligand TGF $\alpha$ , and in this way regulate substrate availability of the enzyme (Surena *et al.*, 2009). However, this mechanism would suggest that overexpression of SAP9 could actually enhance and not inhibit the effect of ADAM-17. Another study used a yeast two-hybrid screening assay to identify a previously unknown protein with SH3 domains as a novel ADAM binding partner. The protein, which they called Eve-1, co-precipitated with ADAM-17 and several other ADAMs in cell lysates (Tanaka, M. *et al.*, 2004). The down-regulation of Eve-1 inhibited shedding of several EGF receptor ligands. ADAM-17 was also shown to interact with the four-and-a-half LIM domain 2 protein (FHL2) at amino acids 721–739. This protein provides a bridge between the actin cytoskeleton and the enzyme (Canault *et al.*, 2006b). Nardilysin (N-arginine dibasic convertase), a metalloendopeptidase of the M16 family was shown to bind both HB-EGF and ADAM-17, and enhance ADAM-17 activity during phorbol ester stimulation (Nishi *et al.*, 2006). The exact site of the interaction was not studied in this case. In another study, the cytoplasmic tail of ADAM-17 together with the cytoplasmic tail of ACE-2 (angiotensin converting enzyme-2) was shown to be necessary for severe acute respiratory syndrome (SARS) coronavirus entry into host cells (Haga *et al.*, 2008). The number of

identified binding partners is increasing, but there is much to learn about the exact mechanisms and consequences of these interactions on ADAM-17 activity. Also, we have no data regarding how the binding of the binding partners is regulated. For example, there is currently no evidence in the literature about whether phosphorylation of ADAM-17 induces changes in the binding of ADAM-17 to regulatory molecules.

### Role of trafficking in ADAM-17 activity regulation

As well as post-translational modification and the regulatory role of binding partners, trafficking can determine ADAM-17 sheddase activity. Recent data showed that after and during furin cleavage, active ADAM-17 is localized separately from its substrate in cholesterol rich membrane domains, lipid rafts, which can thus spatially restrict its activity (Tellier *et al.*, 2006). Furthermore, there is evidence that ERK-dependent threonine 735 phosphorylation is necessary for ADAM-17 to reach the secretory pathway during maturation (Soond *et al.*, 2005). Doedens and Black (2000) showed that PMA but not GPCR stimulation decreased ADAM-17 cell-surface immunostaining. These authors showed internalization and degradation of ADAM-17 molecule. In contrast, another group found that PMA stimulation did not cause ADAM-17 redistribution in the cells; however, the treatment decreased total cellular ADAM-17 content (Diaz-Rodriguez *et al.*, 2002). Despite these observations, *we lack a mechanistic understanding about how ADAM-17 trafficking is regulated*. It would be interesting to see whether binding partners affect ADAM-17 transport. Furthermore, because most studies on the fate of ADAM-17 were carried out in transfected and PMA stimulated cells, we do not know how a physiological stimulus like GPCR activation affects ADAM-17 trafficking. As it was pointed out by a group who analyzed ADAM-17 trafficking, transfected ADAM-17 is processed differently than its endogenous counterpart, and is perhaps not the best model for studying the fate of the endogenously expressed protein (Borroto *et al.*, 2003).

### Structural studies on ADAM-17: how to best target the enzyme activity

In 1998 Maskos *et al.* published the crystal structure of the ADAM-17 catalytic or metalloenzyme domain. This opened up the possibility of designing ADAM-17 inhibitors based on structural similarities to TNF $\alpha$  binding. At the same time, there was intense work to identify and develop selective ADAM-17 inhibitors (reviewed in Newton and Decicco, 1999) either by changing the structure of broad spectrum MMP inhibitors or by designing new compounds (Rabinowitz *et al.*, 2001; Xue *et al.*, 2001; Duan *et al.*, 2002). Improvement of the structure (Ingram



*et al.*, 2006) and description of the crystal structure of the ADAM-17 catalytic domain in complex with its naturally occurring inhibitor, TIMP-3 (Wisniewska *et al.*, 2008), was useful for the recent development of several highly selective potent ADAM-17 inhibitors targeted against the active center (Venkatesan *et al.*, 2004; Gilmore *et al.*, 2006; 2007; Huang, A. *et al.*, 2007). Orally active, selective ADAM inhibitors were developed and tested in combination with ErbB2 receptor antibodies for the treatment of breast cancer (Fridman *et al.*, 2007). The newest inhibitors were promising in that they had none of the musculoskeletal side effects or liver toxicity often observed with previously developed MMP and ADAM inhibitors (for detailed description of structure and effectiveness of ADAM-17 inhibitors, and discussion of clinical trials see Moss *et al.*, 2008, DasGupta *et al.*, 2009). It is noteworthy that current inhibitors target only the enzyme active center and other molecular areas were not explored. Because ADAM-17 is a promiscuous enzyme, we must discover how it is regulated and what proteins it binds to in certain cells to develop potential combinational therapy.

## ADAM-17 in development

### What we learned from knockout studies

The first data on the role of ADAM-17 in development were generated by Peshon's laboratory (Peschon *et al.*, 1998) who found that ADAM-17 knockout mice are not viable and have severe epithelial abnormalities. After creating catalytic domain inactive transgenic animals which lacked the Zn<sup>2+</sup>-binding site of the metalloenzyme domain (ADAM-17  $\Delta$ Zn/ $\Delta$ Zn) they showed that lack of ADAM-17 activity leads to perinatal lethality (between embryonic day 17.5 and birth), likely caused by defects in the placenta and in the fetal lung. Dysregulation of epithelial development led to defects in development of skin, hair, and cornea, and several organs (thyroid, parathyroid, stomach and intestine). Recent investigations also showed that ADAM-17 is important in energy homeostasis, possibly increasing sympathetic outflow; mice with catalytically inactive ADAM-17 have hypermetabolism without increased appetite, which renders the animals extremely lean (Gelling *et al.*, 2008).

The pulmonary hypoplasia seen in ADAM-17 knockout animals was later investigated by Zhao *et al.* (2001), who found that the lungs in ADAM-17-null animals at embryonic day 16.5 had impaired branching morphogenesis and delays in vascularization. Epithelial cell proliferation and differentiation was also delayed as evidenced by repressed gene expression of surfactant-C and aquaporin-5. Newborn ADAM-17-null mice had thicker mesenchyme and fewer peripheral epithelial sacs. Shi and colleagues investigated cardiac development of ADAM-17  $\Delta$ Zn/ $\Delta$ Zn animals and described

enlarged heart (atria and ventricles) at embryonic age 18.5 with hypertrophic, loosely packed cardiac myocytes (Shi *et al.*, 2003). Later Jackson's group reported that newborn ADAM-17 knockout animals have enlarged heart valves similar to HB-EGF-null (Jackson *et al.*, 2003) and EGFR-null mice (Miettinen *et al.*, 1995; Sibilia and Wagner, 1995; Threadgill *et al.*, 1995), and showed that lack of these proteins separately lead to loss of inhibition on bone morphogenic protein (BMP) signaling, which is responsible for abnormal valve thickening (Jackson *et al.*, 2003). Similarities in the phenotype of ADAM-17, EGFR, TGF $\alpha$  (Luetteke *et al.*, 1993; Mann *et al.*, 1993), HB-EGF and amphiregulin knockout mice (Luetteke *et al.*, 1999) is discussed in a recent review (Blobel, 2005).

The role of ADAM-17 sheddase activity was also studied in bone development and in animals with catalytically inactive ADAM-17. Osteoclasts do not move to the diaphysis of metatarsals and therefore do not contribute to normal marrow cavity formation of long bones (Boissy *et al.*, 2003). It seems that a factor (or factors) which is only processed by ADAM-17 is necessary for normal bone marrow cavity formation, but further investigations are needed to identify these molecules. To study the role of ADAM-17 in hematopoiesis, normal mice were irradiated and transplanted with bone marrow of mice with inactive ADAM-17 (Li, N. *et al.*, 2007). Li and co-workers reported that the animals had partially blocked T cell development, and they noted that ADAM-17 is also necessary for peripheral B cell development. The first data with ADAM-17 conditional knockout mouse were published in 2007 by Blobel's group, who inactivated ADAM-17 in myeloid cells and prevented endotoxin-induced lethality of the animals by inhibiting TNF $\alpha$  shedding and preventing increased serum TNF $\alpha$  (Horiuchi *et al.*, 2007). In another study, to characterize the role of ADAM-17 in non-hemopoietic cells, ADAM-17 was conditionally inactivated in mice using Cre recombinase gene expression under the control of the Sox9 transcription factor's promoter, which participates in skeletal development. This maneuver resulted in shortened bones with an osteoporosis-like phenotype characterized by prominent bone loss, and bone marrow hypercellularity and extramedullary hematopoiesis in the liver and spleen (Horiuchi *et al.*, 2009a). These data suggest that conditional knockout animals are useful models for studying cell and tissue-specific roles of ADAM-17 during development and in adult animals.

## ADAM-17 in human diseases

### ADAM-17 in inflammation

Because ADAM-17 was first identified as the TNF- $\alpha$  cleaving enzyme, it was expected that ADAM-17 enzymatic activity would be increased in diseases with increased

circulating or tissue TNF $\alpha$ , such as rheumatoid arthritis and inflammatory bowel disease (Feldmann *et al.*, 1996; Papadakis and Targan, 2000). Indeed, increased TNF $\alpha$  converting enzyme was found in whole cartilage (Patel *et al.*, 1998) and chondrocytes of patients with osteoarthritis (Amin, 1999). Elevated ADAM-17 activity was also reported in synovial tissue of rheumatoid arthritis patients (Ohta *et al.*, 2001). In an experimental model of rheumatoid arthritis, low oxygen and TNF $\alpha$  treatment induced ADAM-17 mRNA expression in synovial cells with a concomitant increase in ADAM-17 activity and TNF $\alpha$  shedding rate (Charbonneau *et al.*, 2007). Upregulated ADAM-17 in monocytes of patients with early systemic sclerosis was reported (Bohgaki *et al.*, 2005). However, there is evidence in the literature which suggests that the role of ADAM-17 in inflammation goes far beyond its effect on TNF $\alpha$  shedding. Chemoattractants in inflamed tissue attract leukocytes from blood which attach and roll on the vascular endothelium near the inflammation site. This attachment is mediated by the transmembrane protein selectins (Spertini *et al.*, 1992). After adhering to the endothelium, leukocytes migrate through the basal membrane, which is promoted by leukocyte (L)-selectin cleavage (Faveeuw *et al.*, 2001). ADAM-17 was identified as the sheddase cleaving L-selectin (Peschon *et al.*, 1998) from macrophages (Condon *et al.*, 2001; Wang, Y. *et al.*, 2009). It was shown that L-selectin co-clustering and cleavage by ADAM-17 is indeed promoted by leukocyte attachment to endothelial or E-selectins (Schaff *et al.*, 2008). There is additional evidence that ADAM-17 cleaves other molecules than L-selectin which participate in leukocyte activation, such as CX3CL1/Fractalkine (Garton *et al.*, 2001; Hundhausen *et al.*, 2003). ADAM-17 also serves as a sheddase for V-CAM (or vascular cell adhesion molecule), the ligand of the leukocyte very late antigen 4 (VLA-4 or  $\alpha 4 \beta 1$  integrin) which mediates leukocyte adhesion to the vascular endothelium (Garton *et al.*, 2003). ADAM-17 also cleaves intercellular adhesion molecule-1 (ICAM-1), which participates in leukocyte adhesion to integrins (Tsakadze *et al.*, 2006). Recently ADAM-17 was implicated in the shedding of the tight junction molecule junctional adhesion molecule-1 (JAM-1) which serves as a zipper between endothelial cells (Koenen *et al.*, 2009). Shedding of JAM-1 can contribute to leukocyte diapedesis through the endothelial layer and the shedded molecule can serve as a biomarker of inflammation. Thus, ADAM-17 was shown to shed several factors contributing to successful recruitment of leukocytes to the inflammation site. Recent studies showed that TIMP-3 knockout animals have increased TNF-dependent systemic immunresponse to both antigen (methylated bovine serum albumin) and LPS-induced inflammation (Mahmoodi *et al.*, 2005; Smookler *et al.*, 2006). Increased degradation of collagen and aggrecan, similar to human osteoarthritis, was also observed in the joints of these

animals (Sahebjam *et al.*, 2007). Furthermore, increased soluble VCAM-release was observed from cytokine stimulated TIMP-3  $-/-$  endothelial cells and aortic explants compared to control (Singh *et al.*, 2005). Synthetic metalloenzyme inhibition (Smookler *et al.*, 2006) or ADAM-17 gene silencing (Singh *et al.*, 2005) rescued the phenotype, suggesting that TIMP-3 is important in balancing ADAM-17 activity during the inflammatory response.

Interestingly, there is some evidence for the anti-inflammatory role of ADAM-17. The enzyme was reported to cleave colony stimulating factor-1 (CSF-1) from the surface of activated macrophages, thereby downregulating their activation (Rovida *et al.*, 2001). Furthermore, ADAM-17 was identified recently as the major sheddase for the IL-15 receptor  $\alpha$  (Budagian *et al.*, 2004), the recombinant soluble form of which was previously shown to inhibit collagen-induced arthritis (Ruchatz *et al.*, 1998) and cardiac allograft rejection. Also, through its role in cleaving IL-6 receptor  $\alpha$  ADAM-17 was implicated in IL-6 trans-signaling, a process which contributes to the decline of neutrophil infiltration and promotes monocyte recruitment, allowing resolution of the inflammation (Marin *et al.*, 2002). However, these data are somewhat contradictory as elevated levels of IL-6 and IL-6-soluble IL6 receptor complex was found in systemic juvenile rheumatoid arthritis (De Benedetti *et al.*, 1994) and Crohn's disease (see below), and IL-6 was implicated in the pathogenesis of these autoimmune diseases. These data suggest that further studies are needed to better characterize the net effect of ADAM-17 in various inflammatory processes.

Because many people are affected by arthritis and inflammation-mediated bone and joint disease, ADAM-17 is under intense investigation as a potential therapeutic target. Metalloenzymes and ADAMs as a target of multi-level therapy (molecular polypharmacy) in osteoarthritis has been recently reviewed (Burrage and Brinckerhoff, 2007) and a recent paper summarizes present knowledge and the advancements made in anti-ADAM-17 therapy in inflammatory disease (Moss *et al.*, 2008).

### Endotoxic shock, sepsis

In a murine model of sepsis, LPS-induced morbidity was inhibited by anti-TNF $\alpha$  antibody, which also inhibited development of arthritis in TNF $\alpha$  transgenic animals (Tsuji *et al.*, 2002). In *Neisseria meningitidis* or LPS-stimulated mononuclear cells, TNF $\alpha$  rapidly decreased from the cell surfaces after stimulation, which supports the role of ADAM-17 in sepsis (Robertshaw and Brennan, 2005). Elevated ADAM-17 was found in blood and peritoneal fluid in patients with peritonitis, and their polymorphonuclear neutrophils had decreased TNF $\alpha$  and L-selectin on their surfaces (Kermarrec *et al.*, 2005). Furthermore, in a recent study, ADAM-17 inactivation in murine myeloid cells prevented endotoxin

shock-induced lethality in mice by inhibiting an increase in circulating TNF $\alpha$ , thus confirming the role of ADAM-17 in this disease (Horiuchi *et al.*, 2007).

During endotoxin shock, growth hormone receptor is shedded from liver cells of LPS-treated nude mice, decreasing cell surface receptor availability, desensitizing the cells for growth hormone, and inhibiting the hormones' anabolic effects (Wang, X. *et al.*, 2008). This mechanism seemed to be independent of ADAM-17: in LPS-treated animals, ADAM-17 was not activated. In another study, investigators showed that selenium treatment was beneficial in endotoxin shock, possibly due to metalloenzyme-dependent L-selectin shedding of monocytes resulting in decreased monocyte rolling (Ahrens *et al.*, 2008). L-selectin cleavage was shown previously to actually promote leukocyte transmigration through the vascular endothelium (see above; Faveeuw *et al.*, 2001). However, it is possible that if L-selectin is cleaved before leukocyte attachment cell rolling can be seriously affected, which would inhibit their transmigration. Sepsis was also shown to inhibit anticoagulatory pathways by downregulating the endothelial protein C receptor (EPCR) through activation of the NF $\kappa$ B pathway (Song *et al.*, 2009). It was shown previously that shedding of EPCR is mediated by ADAM-17 activation, which suggests that the enzyme can contribute to sepsis-induced coagulation (Qu *et al.*, 2007).

### Inflammatory bowel disease

Recently, upregulated ADAM-17 expression in intestinal epithelial cells during the active phase of Crohn's disease was reported (Cesaro *et al.*, 2009). It was also shown that T cells in chronically inflamed intestines of patients with Crohn's disease and colitis are resistant to apoptosis because through their g130 protein they bind an IL-6-soluble IL-6 receptor complex (IL-6-sIL6R) even if they do not have transmembrane IL-6 receptors (Atreya *et al.*, 2000). There is evidence that this signaling, which is called IL-6 trans-signaling, is driven by ADAM-17-mediated shedding of the IL-6 receptor (Briso *et al.*, 2008). Interestingly, this is the same mechanism which was reported to initiate "normal" immune response and resolve inflammation by other investigators (Marin *et al.*, 2002).

### Psoriasis

The beneficial effect of topical MMP/ADAM inhibitors for the treatment of psoriasis was shown in phorbol ester-induced epidermal hyperplasia, in a murine model of the disease (Moriyama *et al.*, 2004). An immunohistological study of psoriatic lesion from patients showed that a wide range of cells, including keratinocytes and blood vessels, but mainly inflammatory cells such as mast cells, expressed high levels of ADAM-17 (Kawaguchi *et al.*, 2005). Peripheral blood mononuclear cells had

elevated ADAM-17 activity and this correlated positively with both plasma soluble TNF-receptor 1 levels and disease severity, which resolved to almost normal levels after patients were treated with narrowband ultraviolet B light (Serwin *et al.*, 2007). It was shown recently that Jun protein controls TNF $\alpha$  shedding in the epidermis by regulating TIMP-3 expression and thus ADAM-17 activation (Guinea-Viniegra *et al.*, 2009). This mechanism can provide an additional therapeutic target for the treatment of psoriasis.

### Pulmonary inflammation

ADAM-17 is expressed in bronchial epithelial cells, vascular smooth muscle cells, and macrophages in the lung (Ermert *et al.*, 2003). Epithelial ADAM-17 was implicated in airway inflammation through cytokine activation during bacterial infection because ADAM-17 co-localized with the IL-6 receptor and initiated its shedding (Gomez *et al.*, 2005). Furthermore, alveolar macrophages produce TNF $\alpha$ , which was shown to activate IL-8 production of lung epithelial cells through amphiregulin and EGFR activation (Chokki *et al.*, 2006). In an animal model of chronic obstructive pulmonary disease, elevated tissue levels of ADAM-17, TNF $\alpha$ , and ErbB3 were observed with increased bronchoalveolar and serum TNF (Ju *et al.*, 2007). ADAM-17 contributed to EGFR-dependent acidic mammalian chitinase secretion of lung epithelial cells, which in turn increased chemokine production of the cells (Hartl *et al.*, 2008). Inhibitors of ADAM-17/MMPs were tested in models of airway inflammation (intranasal LPS challenge) and decreased influx of neutrophils and lymphocytes was found (Trifilieff *et al.*, 2002). Similarly, in a model of acute allergic lung inflammation ADAM-17/MMP inhibitors reduced invasion of neutrophils and eosinophils (Trifilieff *et al.*, 2002). Inhibitors of ADAM-17 also inhibited post-transplantation lung injury in animal models (Goto *et al.*, 2004). However, it was shown that inflammatory mediators such as neutrophil elastase upregulated the MUC1 gene in airway epithelia *in vitro* in an ADAM-17-dependent way and served as a *negative* regulator of airway inflammation (Kuwahara *et al.*, 2007). Furthermore, in TIMP-3 knockout animals, septic lung stress increased lung compliance and severity of disease (Martin *et al.*, 2003). These data again confirm that ADAM-17 can be both a negative and positive regulator of inflammatory processes.

### ADAM-17 in the CNS

#### ADAM-17 in ischemic stroke and brain repair

ADAM-10 and -17 were shown to be present in various regions of the rodent brain by Northern blot analysis (Karkkainen *et al.*, 2000). Immunohistochemical and *in situ* hybridization studies showed that ADAM-17 is expressed in endothelial cells and astrocytes (Goddard



*et al.*, 2001). Both ADAM enzymes were implicated in the development of the nervous system through activating neural cell adhesion and neurite outgrowth by cleaving L1 (Maretzky *et al.*, 2005) and the neuronal cell adhesion molecule, NCAM (Kalus *et al.*, 2006). In pathophysiological states ADAM-17/MMP inhibitors were shown to be beneficial as adjuvant therapy in bacterial meningitis (Meli *et al.*, 2004), possibly due to their inhibition of TNF $\alpha$ -induced leukocyte invasion and extracellular matrix degradation (Leib *et al.*, 2001). ADAM-17 inhibition was effective even in Toll-like receptor 2 (TLR2)-deficient mice and could compensate for the loss of the important anti-inflammatory action of TLR2 in pneumococcal meningitis (Echchannaoui *et al.*, 2007). In oxygen-glucose deprivation, in an *in vitro* model of brain ischemia/reperfusion injury, ADAM-17 was increased in rat forebrain slices with a concomitant increase in inducible nitric oxide synthase (iNOS) (Hurtado *et al.*, 2001). A similar mechanism was observed in long-term and short-term immobilization-induced stress. In this case, glutamate receptor activation induced TNF $\alpha$  shedding and consequent iNOS upregulation through NF- $\kappa$ B signaling, which was inhibited by an ADAM-17 inhibitor, suggesting a neuroprotective effect of ADAM-17 inhibition during stress (Madrigal *et al.*, 2002). Another group, however, showed that ADAM-17-dependent TNF $\alpha$  cleavage actually inhibited apoptosis of neurons through NF $\kappa$ B activation in rat mixed cortical cultures (Hurtado *et al.*, 2002). Also, in ischemic preconditioning, ADAM-17 was increased, protecting the animal brains during a subsequent longer ischemic period by reducing the size of infarction (Cardenas *et al.*, 2002). This mechanism involved upregulation of glutamate receptors (Romera *et al.*, 2004) and TNFR1 (Pradillo *et al.*, 2005). Preconditioning with normobaric hyperoxia seemed to have a similar effect: it also upregulated ADAM-17 and activated NF $\kappa$ B signaling (Bigdeli and Khoshbaten, 2008). ADAM-17 was also shown to be beneficial in a rodent stroke model in which ADAM-17 mediated neurogenesis in the subventricular zone and thus promoted recovery of the animals (Katakowski *et al.*, 2007). Others showed that ADAM-17 can contribute to brain repair by inducing neuronal stem cell proliferation and migration in interaction with the endocannabinoid system (Rubio-Araiz *et al.*, 2008). Furthermore, niacin-induced arteriogenesis after middle cerebral artery occlusion, in a rat stroke model, was mediated by ADAM-17 activation and Notch cleavage (Chen, J. *et al.*, 2009).

In contrast to the above-mentioned findings, in the same middle cerebral artery occlusion model of ischemic stroke, *inhibition* of ADAM-17 activity decreased the infarction size and the authors observed no change in apoptotic cell number upon ADAM-17 inhibition (Wang, X. *et al.*, 2004). Also, ADAM-17 was shown to worsen outcomes of cerebral ischemia during

immobilization stress (Caso *et al.*, 2006). Furthermore, in TIMP-3 knockout animals, cerebral ischemia induced less neuronal death and inflammation in the hippocampus than in wild-type animals (Walker and Rosenberg, 2009). Because there is evidence for both neuroprotective and neurodegenerative effects of ADAM-17, further investigations are needed to characterize the net result of TNF $\alpha$  (and thus ADAM-17)-mediated signaling mechanisms and their consequences during brain injury, and to determine under which circumstances ADAM-17 inhibition is beneficial or harmful. The therapeutic potential of ADAM-17 inhibition in stroke has been discussed in a recent review (Lovering and Zhang, 2005).

### Role of ADAM-17 in memory

The importance of ADAM-17 in learning and memory was also implicated by thorough experiments which showed that the enzyme participates in glutamate receptor 1/5-induced long-term depression (LTD), a cellular model of synaptic plasticity (Cho *et al.*, 2008). ADAM-17 was shown to cleave neuronal pentraxin (NPR) which then binds to AMPA-type glutamate receptors and regulates their endocytosis, a process necessary for LTD in hippocampal and cerebellar synapses. Another protein, the cell adhesion molecule RA175/SynCAM1, which also participates in synaptic connection formation and plasticity, is also processed by ADAM-17-like enzymes on neuronal dendrites (Tanabe *et al.*, 2008). Thus, ADAM-17 has an important role in synaptic formation. Interestingly, it was also shown that TIMP-3 knockout animals have impaired cognitive functions compared to wild-type animals, which may be due to increased MMP activity in the hippocampus (Baba *et al.*, 2009).

### Alzheimer's disease

ADAM-17 has an important role in Alzheimer's disease (AD). As detailed above, ADAM-17 and ADAM-10 act as  $\alpha$ -secretases to cleave amyloid precursor protein (APP) and produce a soluble, non-amyloidogenic fragment, APPs $\alpha$  (Allinson *et al.*, 2003). If APP is cleaved by  $\beta$ -secretase, the resulting product is the amyloidogenic A $\beta$ . Amyloid A $\beta$  peptide can induce the inflammation that is observed in the AD brain, which manifests in microglia and astrocyte activation around amyloid plaques and increased inflammatory mediators (Sastre *et al.*, 2008). Interestingly, ADAM-17 was shown to localize in brain areas which contain amyloid plaques (Skovronsky *et al.*, 2001). Recent work showed that FHL2 (or DRAL), a previously described ADAM-17 cytoplasmic domain partner which influences ADAM-17 activity (Canault *et al.*, 2006b), is necessary for APPs $\alpha$  formation (Tanahashi and Yoshioka, 2008). Other regulators were also reported: the pro-inflammatory cytokine interleukin-1 is capable of enhancing ADAM-17 activity and soluble APP formation in astrocytes, and at the same

time decreases A $\beta$  production (Tachida *et al.*, 2008). Interestingly, interleukin-1 can also stimulate translation of APP in cells (Bandyopadhyay *et al.*, 2007). Increased APPs $\alpha$  production is not always followed by a decrease in A $\beta$  production. In CHO cells expressing APP, ADAM-17 inhibition decreased soluble APP without increasing production of amyloid  $\beta$  peptide (Kim *et al.*, 2008). Other factors which influence APPs $\alpha$  shedding, possibly through ADAM-17 (or ADAM-10) activation, include the acetylcholinesterase inhibitor huperzine A (Peng *et al.*, 2007), the metalloendopeptidase nardilysin (Hiraoka *et al.*, 2007); and the GPCR agonists neuropeptide PACAP and P2Y2R in human astrocytomas (Camden *et al.*, 2005; Kojro *et al.*, 2006). A better understanding of ADAM-17 and ADAM-10 regulation will enhance our knowledge of APP processing regulation and will enable us to design drugs for the treatment of disease.

### ADAM-17 and multiple sclerosis

Based on its role in inflammation, ADAM-17 was implicated in neuroinflammatory disorders including multiple sclerosis (MS) (Moss *et al.*, 1997a). This is supported by data that reflect increased ADAM-17 in peripheral mononuclear cells in patients with active MS (Seifert *et al.*, 2002). Furthermore, ADAM-17 was observed together with TNFR2 in active MS plaques and invading T-lymphocytes in postmortem brain tissue of MS patients using immunohistochemistry (Kieseier *et al.*, 2003). Also, increased amounts of ADAM-17 and soluble TNFR2 was observed in cerebrospinal fluid of MS patients in the same study. Expression of ADAM-17 was thoroughly analyzed in various types of MS, and investigators found that ADAM-17 was highest in secondary progressive and relapsing-remitting MS in relapse (Comabella *et al.*, 2006). ADAM-17 expression was shown in active MS lesions at the time of myeloid breakdown in endothelial cells, microglia, and astrocytes (Plumb *et al.*, 2006). One possible way that ADAM-17 can contribute to plaque formation is to alter growth factor signaling and prolong lesion activity by shedding the tyrosine kinases Axl and Mer decoy receptors in MS (Weinger *et al.*, 2009). However, this possibility warrants further investigation.

### ADAM-17 in malignancies

ADAM-17 was implicated in carcinogenesis because the enzyme sheds growth factors necessary for tumor progression and growth, and because it contributes to inflammation often observed in tumors. In accordance with this finding, increased shedding of epidermal growth factor ligands in tissues was shown to contribute to the development of a malignant phenotype (Katakowski *et al.*, 2009), and elevated expression of ADAMs, including ADAM-17, are usually correlated with poor disease progression

(reviewed recently in Duffy *et al.*, 2009). Even if ADAM-17 has a role in various malignancies (Arribas *et al.*, 2006), at present, the role of ADAM-17 is best studied in breast cancer. ADAM-17 overexpression in breast cancer correlated with TGF $\alpha$  expression (Borrell-Pages *et al.*, 2003), tumor progression, and metastasis (McGowan *et al.*, 2007). Furthermore, increased ADAM-17 was a predictor for shorter survival in breast cancer patients (McGowan *et al.*, 2008). A breast cancer serum marker, nectin-4, which is shed by ADAM-17, was detected in patients with metastatic breast cancer (Fabre-Lafay *et al.*, 2005). *In vitro* ADAM-17 induced proliferation, migration, and tube formation of breast cancer cells through activation of the EGFR-PI3K-AKT pathway (Zheng, X. *et al.*, 2009) and the important pathophysiological role of the enzyme was further confirmed in experiments in which a malignant phenotype of a breast cancer cell line was reverted to normal using small interfering RNAs against ADAM-17 (Kenny and Bissell, 2007).

In ovarian cancer tissues, upregulation of HB-EGF and ADAM-17 was observed, and a positive correlation between HB-EGF and ADAM-17 was found (Tanaka, Y *et al.*, 2005). The authors suggested that the high level of lysophosphatidic acid usually seen in patients with ovarian cancer possibly contributes to cancer progression through EGFR ligand shedding and ADAM-17 activation. The importance of ADAM-17 in cancer invasion also was shown in oral squamous cell carcinoma (Takamune *et al.*, 2008). In this case, TNF $\alpha$  induced NF $\kappa$ B activation which, in turn, contributed to ADAM-17 maturation and induced cancer cell migration. ADAM-17 was increased in primary colon carcinoma (Blanchot-Jossic *et al.*, 2005), in polarized colorectal cancer cells (Merchant *et al.*, 2008), and in *Helicobacter pylori*-positive gastric carcinoma (Yoshimura *et al.*, 2002). Expression of ADAM-17 was higher in nodular hepatocellular carcinoma (HCC) than in solitary large or small HCC (Ding *et al.*, 2004). In hepatocellular carcinoma of nude mice, ADAM-17 silencing resulted in significant decrease in tumorigenesis, invasion, and angiogenesis (Tsai, W.C. *et al.*, 2009), suggesting that ADAM-17 inhibition can be beneficial in this type of cancer. In various lung cancer cell lines, ADAM-17 was identified as a possible novel lung cancer biomarker together with soluble TNFRI (Planque *et al.*, 2009). Increased expression of ADAM-17 was observed in skin malignancies, specifically in invading cells of basal cell carcinoma (Oh *et al.*, 2009). In another study, ADAM-17 expression was observed in 30% of benign prostatic hyperplasia biopsies, and all tumor samples and investigated prostatic tumor cell lines expressed ADAM-17 (Karan *et al.*, 2003). Studying the role of ADAM-17 in brain tumor development, investigators found that overexpression of ADAM-17 in normal cortical astrocytes mediated their conversion into a malignant phenotype, resulting in non-adherent growth, increased

cell proliferation, and production of angiogenic factors (Katakowski *et al.*, 2009). ADAM-17 was also implicated in hematopoietic malignancies through shedding of the tyrosine kinase FLT3 ligand (Horiuchi *et al.*, 2009b). Based on these observations, ADAM-17 is a potentially attractive therapeutic target for the treatment of several malignancies.

### ADAM-17 in angiogenesis

Angiogenesis or new vessel development is not only an important developmental process but it is also indispensable for heart tissue recovery after ischemic episodes, from proliferative retinopathy, or from tumor growth and invasion. Angiogenesis is initiated by vascular endothelial growth factor (VEGF) which stimulates endothelial cells and their progenitors to differentiate and proliferate. The subsequent events include migration of endothelial cells into the surrounding extracellular matrix, where they form cord-like structures (sprouts) which later develop lumens and interconnect. These events are followed by recruitment of accessory cells. Metalloproteinases also have important roles in regulating angiogenesis (Rundhaug, 2005). The significance of ADAM-17 in angiogenesis was first shown in transgenic mice expressing only catalytically inactive ADAM-17. These animals had pulmonary hypovascularization and heart-valve deformities (Zhao *et al.*, 2001; Shi *et al.*, 2003). In a murine model of retinal neovascularization, TNF $\alpha$  was upregulated in the retina during the hypoxia-induced neovascularization period (Majka *et al.*, 2002). Moreover, VEGF induced ADAM-17 activation in retinal microvascular endothelial cells (Majka *et al.*, 2002) and in human umbilical vascular endothelial cells (HUVECs) through ERK activation (Swendeman *et al.*, 2008). A thorough analysis of the role of ADAM-17 in angiogenesis using ADAM-17 silencing revealed that a lack of the enzyme affects invasion and proliferation of the endothelial cells and contributes to destabilization of the developing network of HUVECS (Gooz, P. *et al.*, 2009). Furthermore, ADAM-17 was required for VEGF-induced invasion of HUVECs into a 3D matrix and VEGF-induced expression and activation of MMP-2. The role of ADAM-17 in HUVEC sprouting was confirmed by others (Kwak *et al.*, 2009), and it was also shown that a chemical inhibitor of ADAM-17 inhibited both VEGF-induced tube formation of HUVECs and ischemia-induced retinal neovascularization in mice (Chikaraishi *et al.*, 2009). Similarly, increased angiogenic activity and abnormal choroidal vascularization was observed in the eye of TIMP-3  $-/-$  mice which was attenuated with VEGFR2 inhibition (Janssen *et al.*, 2008). Increased MMP activity was also observed in the eye of the animals, suggesting an important role of TIMP-3 in regulating choroidal vascularization. Further, in the ischemic brain increased arteriogenesis after stroke

was initiated by niacin-induced ADAM-17 upregulation (Chen, J. *et al.*, 2009) as described above. These novel findings emphasize the role of ADAM-17 in angiogenesis both during development and during pathophysiological states such as proliferative retinopathy and stroke. Because the enzyme's expression and activity is upregulated in various cancers, it is possible that other than initiating tumor cell proliferation, ADAM-17 also contributes to tumor neovascularization. Therefore, successful and specific ADAM-17 inhibition could attack tumor proliferation, inflammation and vasculogenesis.

### ADAM-17 in heart diseases and in atherosclerosis

ADAM-17 has an important role in heart development, regulating valvulogenesis and centricular modeling (Shi *et al.*, 2003) but several lines of evidence suggest that it contributes to various heart diseases. ADAM-17 was upregulated together with TNF $\alpha$  in myocarditis and correlated negatively with left ventricular systolic function in patients (Satoh *et al.*, 2000). Increased expression of ADAM-17 was noted in peripheral mononuclear cells (PMNC) of patients with advanced congestive heart failure (Satoh *et al.*, 2004). In patients with acute myocardial infarction ADAM-17 in PMNCs was higher in those subjects who had complications such as malignant recurrent ventricular arrhythmia or pump failure (Shimoda *et al.*, 2005).

In an animal model of concentrated cardiac hypertrophy, ADAM-17 inhibition attenuated development of left ventricle dilatation, perhaps by preserving TNF $\alpha$  on myocyte surfaces because the phenotype was similar to mice expressing non-cleavable TNF $\alpha$  on their myocytes (Dibbs *et al.*, 2003). Dilated cardiomyopathy with increased TNF $\alpha$  activity is also observed in TIMP-3 deficient animals, which further supports the role of ADAM-17 in cardiac remodeling (Fedak *et al.*, 2004). Ablation of TNF $\alpha$  attenuated left ventricular dilatation in these animals, and together with a metalloenzyme inhibitor, rescued the phenotype to normal (Kassiri *et al.*, 2005). Recent data confirmed the role of ADAM-17 in cardiac remodeling both in spontaneous hypertensive rat and in animals treated with angiotensin-II; ADAM-17 knockdown with small interfering RNA inhibited development of both agonist-induced and hypertension-induced cardiac hypertrophy and fibrosis (Wang, X. *et al.*, 2009). Similarly, in TIMP-3 knockout animals L-NAME raised blood pressure less than that observed in wild-type animals, and the hypertension-induced fibrotic changes in vascular walls were also attenuated in the TIMP-3  $-/-$  animals (Higuchi *et al.*, 2007).

Aging of coronary arteries is associated with transition to an inflammatory phenotype and is characterized by an upregulation of TNF $\alpha$  activity which promotes endothelial cell apoptosis (Csizsar *et al.*, 2004). In another study,



investigators showed increased ADAM-17 immunostaining in atherosclerotic plaques of the aortic arch and sinus in apolipoprotein E-deficient mice and in humans (Canault *et al.*, 2006a). At the same time, elevated circulating plasma TNFR I and 2 was also observed. There is also evidence of increased ADAM-17 and TNF $\alpha$  expression in areas of ruptured coronary plaques in patients with myocardial infarction (Sato *et al.*, 2008). These findings strongly suggest that inhibiting ADAM-17 activity can be beneficial for preventing complications of acute myocardial infarction and cardiac remodeling in hypertension.

### ADAM-17 and diabetes

In an animal model of non-obese, insulin-resistant diabetes (hypertensive fructose-fed rats) peritoneally applied ADAM-17 inhibitor restored insulin sensitivity of the animals to normal, which suggests that TNF $\alpha$  inhibition through ADAM-17 could be an attractive treatment for non-obese insulin-resistant diabetes (Togashi *et al.*, 2002). In another publication, heterozygous ADAM-17 (-/+) animals fed a high-fat diet were less prone to obesity and insulin resistance than their wild type littermates (Serino *et al.*, 2007). In diabetes, cardiovascular complications are attributed to low levels of inflammation. In a recent investigation, aldose reductase was shown to be involved in high-glucose-induced TNF $\alpha$  shedding and ADAM-17 activation in rat aortic smooth muscle cells (Reddy *et al.*, 2009). Inhibition of aldose reductase by sorbitol decreased shedded TNF $\alpha$  both in cell culture and in rats with streptozotocin-induced diabetes, suggesting that the enzyme could be a therapeutic target for treating diabetes-induced vascular inflammation. Similarly, decreased TIMP-3 was implicated in inflammation and insulin resistance; and hepatic steatosis, liver and fat tissue inflammation was observed in TIMP-3 knockout animals fed a high-fat diet (Menghini *et al.*, 2009). This suggests that increased ADAM-17 could be important in obesity-associated fatty liver disease.

Interestingly, ADAM-17 as  $\alpha$ -secretase was also shown to cleave Klotho, an anti-aging protein expressed mainly in the kidney and brain (Bloch *et al.*, 2009). Klotho also regulates glucose metabolism: Klotho knockdown animals have low blood insulin levels and are hypersensitive to exogenous insulin (Utsugi *et al.*, 2000). Regulating Klotho could provide another control point for ADAM-17 to influence glucose homeostasis.

### ADAM-17 in kidney disease

Increased activation of the EGFR through TGF $\alpha$  or HB-EGF was shown in several kidney diseases including polycystic kidney disease (Richards *et al.*, 1998). In bpk

mice, a model of autosomal recessive polycystic kidney disease (PKD), increased TGF $\alpha$  immunostaining was found in the proximal tubules of cystic kidneys (Dell *et al.*, 2001). ADAM-17 inhibitor treatment significantly decreased cyst formation and improved kidney function. Another group showed that TGF $\alpha$  knockout bpk mice also developed PKD, suggesting that other ADAM-17 substrates can be responsible for the phenotype (Nemo *et al.*, 2005). Indeed, EGF, amphiregulin, HB-EGF, EGFR and ErbB4 are overexpressed in polycystic kidney disease, and all could be substrates of ADAM-17. Chronic kidney disease (CKD), which is characterized by extracellular matrix deposition and fibrotic transformation of kidney tissue, can develop from renal diseases of different origins. Because angiotensin converting enzyme inhibitors slowed disease progression, the role of angiotensin-II in CKD was studied intensively. Data are accumulating to suggest that increased EGFR activation can contribute to the fibrotic process, and it was shown that the GPCR agonist angiotensin-II induces EGFR transactivation by ADAM-17 activation and TGF $\alpha$  shedding (Lautrette *et al.*, 2005). Chemical inhibition of ADAM-17 attenuated chronic angiotensin-II-induced glomerular fibrosis, suggesting that ADAM-17 inhibition can be a valuable therapeutic tool in treating fibrotic kidney disease. In TGF $\alpha$  knockout mice, chronic angiotensin-II infusion-induced proteinuria, tubular atrophy, and glomerulosclerosis were greatly attenuated compared to wild type, angiotensin-II treated animals (Shah and Catt, 2006). In TIMP-3 -/- animals, unilateral ureteral obstruction, an experimental model of interstitial kidney fibrosis, led to increased renal injury compared to wild-type animals (Kassiri *et al.*, 2009). The increased fibrosis and inflammation that was accompanied with elevated ADAM-17 activity was attenuated with additional TNF $\alpha$  ablation. In an *in vitro* model of glomerular disease, angiotensin-II induced HB-EGF shedding from mesangial cells (Uchiyama-Tanaka *et al.*, 2001). In another study, the pro-fibrotic GPCR agonist, serotonin, was shown to stimulate EGFR activation and proliferation of mesangial cells through ADAM-17-mediated HB-EGF shedding (Gooz, M. *et al.*, 2006). Downregulating ADAM-17 by silencing RNA completely inhibited the effect of serotonin. In mesangial cells, the chemokine CXCL16 is shed by ADAM-17 and ADAM-10 (Schramme *et al.*, 2008). Inhibiting metalloenzyme activity in mesangial cells inhibited T-Jurkat cell chemotaxis, and silencing either CXCL16 or ADAM-17 expression attenuated proliferation of mesangial cells. These data show that ADAM-17 can be an exciting novel target for the treatment of kidney diseases. Because many people are affected by chronic kidney disease – 1 in 10 people in the USA, based on the National Kidney Foundation <http://www.nkf.org> – and as presently ACE inhibitors are the only therapy available to

slow CKD progression, therapeutic targeting of ADAM-17 in kidney diseases should be considered and investigated more intensively.

## Concluding remarks

ADAM-17 is expressed by most mammalian cells and may have a role in controlling many physiological and pathophysiological processes. It is indispensable for normal mammalian development and, through its contribution as an important sheddase, it is indispensable for adult life. The number of identified ADAM-17 substrates is increasing and evidence is mounting that ADAM-17 has a role in almost every cellular function. Because of the ubiquitous nature of the enzyme, mechanisms for controlling ADAM-17 activity are worth investigating. For example, how to specifically target ADAM-17 in cancer or in kidney disease without targeting the function of the enzyme in other tissues is a concern. Even with specific inhibitors that inhibit only ADAM-17 and no other metalloenzymes, the side effects would be enormous. Also, the dual nature of ADAM-17 (it is both pro-proliferative and inhibitory) is problematic because some effects may be beneficial for some tissues or diseases and harmful in others. Because ADAM-17 activity must be regarded in its full cellular context, molecules binding to the enzymes and signaling pathways interconnected with the ADAM-17 signaling pathway all have unique cell- and tissue-specific effects which influence the outcome of ADAM-17 activation. We are only beginning to understand the effect of post-translational modifications on the enzyme activity and its role in ADAM-17 interactions and trafficking. In addition, we have data regarding phorbol ester-induced activation of the enzyme, and these experiments, while providing valuable data – such as a list of molecules cleaved by the enzyme – do not tell us specifically which molecules regulate ADAM-17 activity. Understanding ADAM-17 activity regulation *in vivo* is crucial for the development of adequate patient therapy.

## Acknowledgements

I am thankful for Dr. Pal Gooz for critical reading of the manuscript and for Dr. Jennifer Schnellmann at the Office of Scientific Editing and Publications at the Medical University of South Carolina for critical reading and editing the manuscript.

## Declaration of interest

This work was supported by grants from the National Institutes of Health (NIH/NIDDK K01 DK070054 and

NIH/NIDDK ARRA supplement 3K01DK070054-05S1) and from the Paul Teschan Research Fund of the Dialysis Clinic, Inc.

## References

- Ahrens I, Ellwanger C, Smith BK, Bassler N, Chen YC, Neudorfer I, Ludwig A, Bode C and Peter K. 2008. Selenium supplementation induces metalloproteinase-dependent L-selectin shedding from monocytes. *J Leukoc Biol* 83:1388–1395.
- Alfa Cisse M, Sunyach C, Slack BE, Fisher A, Vincent B and Checler F. 2007. M1 and M3 muscarinic receptors control physiological processing of cellular prion by modulating ADAM17 phosphorylation and activity. *J Neurosci* 27:4083–4092.
- Allinson TM, Parkin ET, Turner AJ and Hooper NM. 2003. ADAMs family members as amyloid precursor protein alpha-secretases. *J Neurosci Res* 74:342–352.
- Amin AR. 1999. Regulation of tumor necrosis factor-alpha and tumor necrosis factor converting enzyme in human osteoarthritis. *Osteoarthritis Cartilage* 7:392–394.
- Amour A, Slocumbe PM, Webster A, Butler M, Knight CG, Smith BJ, Stephens PE, Shelley C, Hutton M, Knauper V, Docherty AJ and Murphy G. 1998. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. *FEBS Lett* 435:39–44.
- Anderson JP, Chen Y, Kim KS and Robakis NK. 1992. An alternative secretase cleavage produces soluble Alzheimer amyloid precursor protein containing a potentially amyloidogenic sequence. *J Neurochem* 59:2328–2331.
- Arribas J, Bech-Serra JJ and Santiago-Josefat B. 2006. ADAMs, cell migration and cancer. *Cancer Metastasis Rev* 25:57–68.
- Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S and Neurath MF. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis *in vivo*. *Nat Med* 6:583–588.
- Baba Y, Yasuda O, Takemura Y, Ishikawa Y, Ohishi M, Iwanami J, Mogi M, Doe N, Horiuchi M, Maeda N, Fukuo K and Rakugi H. 2009. Timp-3 deficiency impairs cognitive function in mice. *Lab Invest* 89:1340–1347.
- Bandyopadhyay S, Goldstein LE, Lahiri DK and Rogers JT. 2007. Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease. *Curr Med Chem* 14:2848–2864.
- Bao J, Wolpowitz D, Role LW and Talmage DA. 2003. Back signaling by the Nrg-1 intracellular domain. *J Cell Biol* 161:1133–1141.
- Bax DV, Messent AJ, Tart J, van Hoang M, Kott J, Maciewicz RA and Humphries MJ. 2004. Integrin alpha5beta1 and ADAM-17 interact *in vitro* and co-localize in migrating HeLa cells. *J Biol Chem* 279:22377–22386.
- Bigdeli MR and Khoshbaten A. 2008. *In vivo* preconditioning with normobaric hyperoxia induces ischemic tolerance partly by triggering tumor necrosis factor-alpha converting enzyme/tumor necrosis factor-alpha/nuclear factor-kappaB. *Neuroscience* 153:671–678.
- Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson ME, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ and Cerretti DP. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. *Nature* 385:729–733.
- Blanchot-Jossic F, Jarry A, Masson D, Bach-Ngohou K, Paineau J, Denis MG, Laboisie CL and Mosnier JF. 2005. Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. *J Pathol* 207:156–163.
- Blobel CP. 2005. ADAMs: key components in EGFR signalling and development. *Nat Rev Mol Cell Biol* 6:32–43.

- Bloch L, Sineshchekova O, Reichenbach D, Reiss K, Saftig P, Kuro-o M and Kaether C. 2009. Klotho is a substrate for alpha-, beta- and gamma-secretase. *FEBS Lett* 583:3221-3224.
- Bohgaki T, Amasaki Y, Nishimura N, Bohgaki M, Yamashita Y, Nishio M, Sawada KI, Jodo S, Atsumi T and Koike T. 2005. Up regulated expression of tumour necrosis factor  $\alpha$  converting enzyme in peripheral monocytes of patients with early systemic sclerosis. *Ann Rheum Dis* 64:1165-1173.
- Boissy P, Lenhard TR, Kirkegaard T, Peschon JJ, Black RA, Delaisie JM and del Carmen Ovejero M. 2003. An assessment of ADAMs in bone cells: absence of TACE activity prevents osteoclast recruitment and the formation of the marrow cavity in developing long bones. *FEBS Lett* 553:257-261.
- Borrell-Pages M, Rojo F, Albanell J, Baselga J and Arribas J. 2003. TACE is required for the activation of the EGFR by TGF- $\alpha$  in tumors. *EMBO J* 22:1114-1124.
- Borroto A, Ruiz-Paz S, de la Torre TV, Borrell-Pages M, Merlos-Suarez A, Pandiella A, Blobel CP, Baselga J and Arribas J. 2003. Impaired trafficking and activation of tumor necrosis factor- $\alpha$ -converting enzyme in cell mutants defective in protein ectodomain shedding. *J Biol Chem* 278:25933-25939.
- Bridges LC and Bowditch RD. 2005. ADAM-integrin interactions: potential integrin regulated ectodomain shedding activity. *Curr Pharm Des* 11:837-847.
- Briso EM, Dienz O and Rincon M. 2008. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. *J Immunol* 180:7102-7106.
- Brodowicz T, Wiltschke C, Budinsky AC, Krainer M, Steger GG and Zielinski CC. 1997. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. *Int J Cancer* 73:875-879.
- Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA and Israel A. 2000. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. *Mol Cell* 5:207-216.
- Buckley CA, Rouhani FN, Kaler M, Adamik B, Hawari FI and Levine SJ. 2005. Amino-terminal TACE prodomain attenuates TNFR2 cleavage independently of the cysteine switch. *Am J Physiol Lung Cell Mol Physiol* 288:L1132-1138.
- Budagian V, Bulanov E, Orinska Z, Ludwig A, Rose-John S, Saftig P, Borden EC and Bulfone-Paus S. 2004. Natural soluble interleukin-15 $\alpha$  is generated by cleavage that involves the tumor necrosis factor- $\alpha$ -converting enzyme (TACE/ADAM17). *J Biol Chem* 279:40368-40375.
- Burrage PS and Brinckerhoff CE. 2007. Molecular targets in osteoarthritis: metalloproteinases and their inhibitors. *Curr Drug Targets* 8:293-303.
- Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP and Black RA. 1998. Evidence that tumor necrosis factor  $\alpha$  converting enzyme is involved in regulated  $\alpha$ -secretase cleavage of the Alzheimer amyloid protein precursor. *J Biol Chem* 273:27765-27767.
- Caescu CI, Jeschke GR and Turk BE. 2009. Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. *Biochem J* 424:79-88.
- Calvete JJ. 2005. Structure-function correlations of snake venom disintegrins. *Curr Pharm Des* 11:829-835.
- Calvete JJ, Moreno-Murciano MP, Theakston RD, Kisiel DG and Marcinkiewicz C. 2003. Snake venom disintegrins: novel dimeric disintegrins and structural diversification by disulphide bond engineering. *Biochem J* 372:725-734.
- Calvete JJ, Marcinkiewicz C and Sanz L. 2007. KTS and RTS-disintegrins: anti-angiogenic viper venom peptides specifically targeting the  $\alpha$ 1  $\beta$ 1 integrin. *Curr Pharm Des* 13:2853-2859.
- Camden JM, Schrader AM, Camden RE, Gonzalez FA, Erb L, Seye CI and Weisman GA. 2005. P2Y2 nucleotide receptors enhance  $\alpha$ -secretase-dependent amyloid precursor protein processing. *J Biol Chem* 280:18696-18702.
- Canault M, Peiretti F, Kopp F, Bonardo B, Bonzi ME, Coudeyre JC, Alessi MC, Juhan-Vague I and Nalbone G. 2006a. The TNF  $\alpha$  converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF  $\alpha$  receptors. *Atherosclerosis* 187:82-91.
- Canault M, Tellier E, Bonardo B, Mas E, Aumailley M, Juhan-Vague I, Nalbone G and Peiretti F. 2006b. FHL2 interacts with both ADAM-17 and the cytoskeleton and regulates ADAM-17 localization and activity. *J Cell Physiol* 208:363-372.
- Cardenas A, Moro MA, Leza JC, O'Shea E, Davalos A, Castillo J, Lorenzo P and Lizasoain I. 2002. Upregulation of TACE/ADAM17 after ischemic preconditioning is involved in brain tolerance. *J Cereb Blood Flow Metab* 22:1297-1302.
- Caso JR, Lizasoain I, Lorenzo P, Moro MA and Leza JC. 2006. The role of tumor necrosis factor- $\alpha$  in stress-induced worsening of cerebral ischemia in rats. *Neuroscience* 142:59-69.
- Cesaro A, Abakar-Mahamat A, Brest P, Lassalle S, Selva E, Filippi J, Hebuterne X, Hugot JP, Doglio A, Galland E, Naquet P, Vouret-Craviari V, Mograbi B and Hofman PM. 2009. Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia. *Am J Physiol Gastrointest Liver Physiol* 296:G1332-1343.
- Charbonneau M, Harper K, Grondin F, Pelmus M, McDonald PP and Dubois CM. 2007. Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor  $\alpha$ -induced increases in tumor necrosis factor- $\alpha$  converting enzyme/ADAM17 expression by synovial cells. *J Biol Chem* 282:33714-33724.
- Charrier-Hisamuddin L, Laboisse CL and Merlin D. 2008. ADAM-15: a metalloprotease that mediates inflammation. *FASEB J* 22:641-653.
- Chen B, Bronson RT, Klamon LD, Hampton TG, Wang JF, Green PJ, Magnuson T, Douglas PS, Morgan JP and Neel BG. 2000. Mice mutant for *Egfr* and *Shp2* have defective cardiac semilunar valvulogenesis. *Nat Genet* 24:296-299.
- Chen J, Cui X, Zacharek A, Ding GL, Shehadah A, Jiang Q, Lu M and Chopp M. 2009. Niaspan treatment increases tumor necrosis factor- $\alpha$ -converting enzyme and promotes arteriogenesis after stroke. *J Cereb Blood Flow Metab* 29:911-920.
- Chen MS, Almeida EA, Huovila AP, Takahashi Y, Shaw LM, Mercurio AM and White JM. 1999. Evidence that distinct states of the integrin  $\alpha$ 6 $\beta$ 1 interact with laminin and an ADAM. *J Cell Biol* 144:549-561.
- Chikaraishi Y, Shimazawa M, Yokota K, Yoshino K and Hara H. 2009. CB-12181, a new azasugar-based matrix metalloproteinase/tumor necrosis factor- $\alpha$  converting enzyme inhibitor, inhibits vascular endothelial growth factor-induced angiogenesis in vitro and retinal neovascularization in vivo. *Curr Neurovasc Res* 6:140-147.
- Cho RW, Park JM, Wolff SB, Xu D, Hopf C, Kim JA, Reddy RC, Petralia RS, Perin MS, Linden DJ and Worley PF. 2008. mGluR1/5-dependent long-term depression requires the regulated ectodomain cleavage of neuronal pentraxin NPR by TACE. *Neuron* 57:858-871.
- Chokki M, Mitsunashi H and Kamimura T. 2006. Metalloprotease-dependent amphiregulin release mediates tumor necrosis factor- $\alpha$ -induced IL-8 secretion in the human airway epithelial cell line NCI-H292. *Life Sci* 78:3051-3057.
- Chung KH, Kim SH, Han KY, Sohn YD, Chang SI, Baek KH, Jang Y, Kim DS and Kang IC. 2003. Inhibitory effect of salmosin, a Korean snake venom-derived disintegrin, on the integrin  $\alpha$ 5 $\beta$ 1-mediated proliferation of SK-Mel-2 human melanoma cells. *J Pharm Pharmacol* 55:1577-1582.
- Citri A, Skaria KB and Yarden Y. 2003. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. *Exp Cell Res* 284:54-65.
- Comabella M, Romera C, Camina M, Perkal H, Moro MA, Leza JC, Lizasoain I, Castillo M and Montalban X. 2006. TNF- $\alpha$  converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis. *J Neurol* 253:701-706.
- Cominetti MR, Ribeiro JU, Fox JW and Selistre-de-Araujo HS. 2003. BaG, a new dimeric metalloproteinase/disintegrin from the *Bothrops alternatus* snake venom that interacts with  $\alpha$ 5 $\beta$ 1 integrin. *Arch Biochem Biophys* 416:171-179.
- Condon TP, Flournoy S, Sawyer GJ, Baker BF, Kishimoto TK and Bennett CE. 2001. ADAM17 but not ADAM10 mediates tumor necrosis factor- $\alpha$  and L-selectin shedding from leukocyte membranes. *Antisense Nucleic Acid Drug Dev* 11:107-116.
- Csiszar A, Ungvari Z, Koller A, Edwards JG and Kaley G. 2004. Proinflammatory phenotype of coronary arteries promotes endothelial apoptosis in aging. *Physiol Genomics* 17:21-30.



- Danen EH, Marcinkiewicz C, Cornelissen IM, van Kraats AA, Pachter JA, Ruiter DJ, Niewiarowski S and van Muijen GN. 1998. The disintegrin ristostatin interferes with integrin alpha 4 beta 1 function and with experimental metastasis of human melanoma cells. *Exp Cell Res* 238:188-196.
- DasGupta S, Murumkar PR, Giridhar R and Yadav MR. 2009. Current perspective of TACE inhibitors: a review. *Bioorg Med Chem* 17:444-459.
- De Benedetti F, Massa M, Pignatti P, Albani S, Novick D and Martini A. 1994. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. *J Clin Invest* 93:2114-2119.
- Dell KM, Nemo R, Sweeney WE, Jr, Levin JL, Frost P and Avner ED. 2001. A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease. *Kidney Int* 60:1240-1248.
- De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A and Kopan R. 1999. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. *Nature* 398:518-522.
- Diaz-Rodriguez E, Montero JC, Esparis-Ogando A, Yuste L and Pandiella A. 2002. Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. *Mol Biol Cell* 13:2031-2044.
- Dibbs ZI, Diwan A, Nemoto S, DeFreitas G, Abdellatif M, Carabello BA, Spinale FG, Feuerstein G, Sivasubramanian N and Mann DL. 2003. Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype. *Circulation* 108:1002-1008.
- Ding X, Yang LY, Huang GW, Wang W and Lu WQ. 2004. ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. *World J Gastroenterol* 10:2735-2739.
- Doedens JR and Black RA. 2000. Stimulation-induced down-regulation of tumor necrosis factor-alpha converting enzyme. *J Biol Chem* 275:14598-14607.
- Doedens JR, Mahimkar RM and Black RA. 2003. TACE/ADAM-17 enzymatic activity is increased in response to cellular stimulation. *Biochem Biophys Res Commun* 308:331-338.
- Duan JJ, Chen L, Wasserman ZR, Lu Z, Liu RQ, Covington MB, Qian M, Hardman KD, Magolda RL, Newton RC, Christ DD, Wexler RR and Decicco CP. 2002. Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships. *J Med Chem* 45:4954-4957.
- Duffy MJ, McKiernan E, O'Donovan N and McGowan PM. 2009. Role of ADAMs in cancer formation and progression. *Clin Cancer Res* 15:1140-1144.
- Echchannaoui H, Leib SL, Neumann U and Landmann RM. 2007. Adjuvant TACE inhibitor treatment improves the outcome of TLR2-/- mice with experimental pneumococcal meningitis. *BMC Infect Dis* 7:25.
- Edwards DR, Handsley MM and Pennington CJ. 2008. The ADAM metalloproteinases. *Mol Aspects Med* 29:258-289.
- Ermert M, Pantazis C, Duncker HR, Grimminger F, Seeger W and Ermert L. 2003. In situ localization of TNFalpha/beta, TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue. *Cytokine* 22:89-100.
- Eto K, Puzon-McLaughlin W, Sheppard D, Sehara-Fujisawa A, Zhang XP and Takada Y. 2000. RGD-independent binding of integrin alpha9beta1 to the ADAM-12 and -15 disintegrin domains mediates cell-cell interaction. *J Biol Chem* 275:34922-34930.
- Fabre-Lafay S, Garrido-Urbani S, Reymond N, Goncalves A, Dubreuil P and Lopez M. 2005. Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. *J Biol Chem* 280:19543-19550.
- Fahrenholz F, Gilbert S, Kojro E, Lammich S and Postina R. 2000. Alpha-secretase activity of the disintegrin metalloprotease ADAM 10. Influences of domain structure. *Ann NY Acad Sci* 920:215-222.
- Fan H, Turck CW and Derynck R. 2003. Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor-alpha converting enzyme and of an alternatively translated polypeptide. *J Biol Chem* 278:18617-18627.
- Faveeuw C, Preece G and Ager A. 2001. Transendothelial migration of lymphocytes across high endothelial venules into lymph nodes is affected by metalloproteinases. *Blood* 98:688-695.
- Fedak PW, Smookler DS, Kassiri Z, Ohno N, Leco KJ, Verma S, Mickle DA, Watson KL, Hojilla CV, Cruz W, Weisel RD, Li RK and Khokha R. 2004. TIMP-3 deficiency leads to dilated cardiomyopathy. *Circulation* 110:2401-2409.
- Feldmann M, Brennan FM, Elliott MJ, Williams RO and Maini RN. 1995. TNF alpha is an effective therapeutic target for rheumatoid arthritis. *Ann NY Acad Sci* 766:272-278.
- Feldmann M, Brennan FM and Maini RN. 1996. Role of cytokines in rheumatoid arthritis. *Annu Rev Immunol* 14:397-440.
- Fridman JS, Caulder E, Hansbury M, Liu X, Yang G, Wang Q, Lo Y, Zhou BB, Pan M, Thomas SM, Grandis JR, Zhuo J, Yao W, Newton RC, Friedman SM, Scherle PA and Vaddi K. 2007. Selective inhibition of ADAM metalloproteinases as a novel approach for modulating ErbB pathways in cancer. *Clin Cancer Res* 13:1892-1902.
- Galan JA, Sanchez EE, Rodriguez-Acosta A, Soto JG, Bashir S, McLane MA, Paquette-Straub C and Perez JC. 2008. Inhibition of lung tumor colonization and cell migration with the disintegrin crotatroxin 2 isolated from the venom of *Crotalus atrox*. *Toxicon* 51:1186-1196.
- Galvin KM, Donovan MJ, Lynch CA, Meyer RI, Paul RJ, Lorenz JN, Fairchild-Huntress V, Dixon KL, Dunmore JH, Gimbrone MA, Jr, Falb D and Huszar D. 2000. A role for smad6 in development and homeostasis of the cardiovascular system. *Nat Genet* 24:171-174.
- Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ and Raines EW. 2001. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). *J Biol Chem* 276:37993-38001.
- Garton KJ, Gough PJ, Philalay J, Wille PT, Blobel CP, Whitehead RH, Dempsey PJ and Raines EW. 2003. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). *J Biol Chem* 278:37459-37464.
- Gelling RW, Yan W, Al-Noori S, Pardini A, Morton GJ, Ogimoto K, Schwartz MW and Dempsey PJ. 2008. Deficiency of TNFalpha converting enzyme (TACE/ADAM17) causes a lean, hypermetabolic phenotype in mice. *Endocrinology* 149:6053-6064.
- Giancotti FG and Ruoslahti E. 1999. Integrin signaling. *Science* 285:1028-1032.
- Gilmore JL, King BW, Harris C, Maduskuie T, Mercer SE, Liu RQ, Covington MB, Qian M, Ribadeneria MD, Vaddi K, Trzaskos JM, Newton RC, Decicco CP and Duan JJ. 2006. Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. *Bioorg Med Chem Lett* 16:2699-2704.
- Gilmore JL, King BW, Asakawa N, Harrison K, Tebben A, Sheppeck JE, 2nd, Liu RQ, Covington M and Duan JJ. 2007. Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors. *Bioorg Med Chem Lett* 17:4678-4682.
- Goddard DR, Bunning RA and Woodroffe MN. 2001. Astrocyte and endothelial cell expression of ADAM 17 (TACE) in adult human CNS. *Glia* 34:267-271.
- Gomez MI, Sokol SH, Muir AB, Soong G, Bastien J and Prince AS. 2005. Bacterial induction of TNF-alpha converting enzyme expression and IL-6 receptor alpha shedding regulates airway inflammatory signaling. *J Immunol* 175:1930-1936.
- Gonzales PE, Solomon A, Miller AB, Leesnitzer MA, Sagi I and Milla ME. 2004. Inhibition of the tumor necrosis factor-alpha-converting enzyme by its pro domain. *J Biol Chem* 279:31638-31645.
- Gonzales PE, Galli JD and Milla ME. 2008. Identification of key sequence determinants for the inhibitory function of the prodomain of TACE. *Biochemistry* 47:9911-9919.
- Gooz M, Gooz P, Luttrell LM and Raymond JR. 2006. 5-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-alpha-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-

- like growth factor (HB-EGF) shedding in mesangial cells. *J Biol Chem* 281:21004-21012.
- Gooz P, Gooz M, Baldys A and Hoffman S. 2009. ADAM-17 regulates endothelial cell morphology, proliferation, and in vitro angiogenesis. *Biochem Biophys Res Commun* 380:33-38.
- Goto T, Ishizaka A, Kobayashi F, Kohno M, Sawafuji M, Tasaka S, Ikeda E, Okada Y, Maruyama I and Kobayashi K. 2004. Importance of tumor necrosis factor- $\alpha$  cleavage process in post-transplantation lung injury in rats. *Am J Respir Crit Care Med* 170:1239-1246.
- Gschwind A, Hart S, Fischer OM and Ullrich A. 2003. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. *EMBO J* 22:2411-2421.
- Guinea-Viniegra J, Zenz R, Scheuch H, Hnisz D, Holcman M, Bakiri L, Schonthaler HB, Sibilia M and Wagner EF. 2009. TNF $\alpha$  shedding and epidermal inflammation are controlled by Jun proteins. *Genes Dev* 23:2663-2674.
- Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, Sasazuki T and Ishizaka Y. 2008. Modulation of TNF- $\alpha$ -converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF- $\alpha$  production and facilitates viral entry. *Proc Natl Acad Sci USA* 105:7809-7814.
- Hartl D, He CH, Koller B, Da Silva CA, Homer R, Lee CG and Elias JA. 2008. Acidic mammalian chitinase is secreted via an ADAM17/epidermal growth factor receptor-dependent pathway and stimulates chemokine production by pulmonary epithelial cells. *J Biol Chem* 283:33472-33482.
- Hartmann D, Tournoy J, Saftig P, Annaert W and De Strooper B. 2001. Implication of APP secretases in notch signaling. *J Mol Neurosci* 17:171-181.
- Higashiyama S and Nanba D. 2005. ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. *Biochim Biophys Acta* 1751:110-117.
- Higuchi M, Yasuda O, Kawamoto H, Yotsui T, Baba Y, Ozaki T, Maeda N, Fukuo K, Rakugi H and Ogihara T. 2007. Tissue inhibitor of metalloproteinase-3 deficiency inhibits blood pressure elevation and myocardial microvascular remodeling induced by chronic administration of Nomega-nitro-L-arginine methyl ester in mice. *Hypertens Res* 30:563-571.
- Hinkle CL, Sunnarborg SW, Loiselle D, Parker CE, Stevenson M, Russell WE and Lee DC. 2004. Selective roles for tumor necrosis factor  $\alpha$ -converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family: the juxtamembrane stalk determines cleavage efficiency. *J Biol Chem* 279:24179-24188.
- Hiraoka Y, Ohno M, Yoshida K, Okawa K, Tomimoto H, Kita T and Nishi E. 2007. Enhancement of  $\alpha$ -secretase cleavage of amyloid precursor protein by a metalloendopeptidase nardilysin. *J Neurochem* 102:1595-1605.
- Horiuchi K, Kimura T, Miyamoto T, Takaishi H, Okada Y, Toyama Y and Blobel CP. 2007. Cutting edge: TNF- $\alpha$ -converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. *J Immunol* 179:2686-2689.
- Horiuchi K, Kimura T, Miyamoto T, Miyamoto K, Akiyama H, Takaishi H, Morioka H, Nakamura T, Okada Y, Blobel CP and Toyama Y. 2009a. Conditional inactivation of TACE by a Sox9 promoter leads to osteoporosis and increased granulopoiesis via dysregulation of IL-17 and G-CSF. *J Immunol* 182:2093-2101.
- Horiuchi K, Morioka H, Takaishi H, Akiyama H, Blobel CP and Toyama Y. 2009b. Ectodomain shedding of FLT3 ligand is mediated by TNF- $\alpha$  converting enzyme. *J Immunol* 182:7408-7414.
- Huang A, Joseph-McCarthy D, Lovering F, Sun L, Wang W, Xu W, Zhu Y, Cui J, Zhang Y and Levin JJ. 2007. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket. *Bioorg Med Chem* 15:6170-6181.
- Huang J, Bridges LC and White JM. 2005. Selective modulation of integrin-mediated cell migration by distinct ADAM family members. *Mol Biol Cell* 16:4982-4991.
- Huang TF, Holt JC, Lukasiewicz H and Niewiarowski S. 1987. Trigrinin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex. *J Biol Chem* 262:16157-16163.
- Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen KJ, Rose-John S and Ludwig A. 2003. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. *Blood* 102:1186-1195.
- Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I and Ortiz RM. 2005. Shedding light on ADAM metalloproteinases. *Trends Biochem Sci* 30:413-422.
- Hurtado O, Cardenas A, Lizasoain I, Bosca L, Leza JC, Lorenzo P and Moro MA. 2001. Up-regulation of TNF- $\alpha$  convertase (TACE/ADAM17) after oxygen-glucose deprivation in rat forebrain slices. *Neuropharmacology* 40:1094-1102.
- Hurtado O, Lizasoain I, Fernandez-Tome P, Alvarez-Barrientos A, Leza JC, Lorenzo P and Moro MA. 2002. TACE/ADAM17-TNF- $\alpha$  pathway in rat cortical cultures after exposure to oxygen-glucose deprivation or glutamate. *J Cereb Blood Flow Metab* 22:576-585.
- Huveneers S, Truong H and Danen HJ. 2007. Integrins: signaling, disease, and therapy. *Int J Radiat Biol* 83:743-751.
- Huxley-Jones J, Clarke TK, Beck C, Toubaris G, Robertson DL and Boot-Handford RP. 2007. The evolution of the vertebrate metzincins; insights from *Ciona intestinalis* and *Danio rerio*. *BMC Evol Biol* 7:63.
- Ingram RN, Orth P, Strickland CL, Le HV, Madison V and Beyer BM. 2006. Stabilization of the autoproteolysis of TNF- $\alpha$  converting enzyme (TACE) results in a novel crystal form suitable for structure-based drug design studies. *Protein Eng Des Sel* 19:155-161.
- Jackson LE, Qiu TH, Sunnarborg SW, Chang A, Zhang C, Patterson C and Lee DC. 2003. Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. *Embo J* 22:2704-2716.
- Janssen A, Hoellenriegel J, Fogarasi M, Schrewe H, Seeliger M, Tamm E, Ohlmann A, May CA, Weber BH and Stohr H. 2008. Abnormal vessel formation in the choroid of mice lacking tissue inhibitor of metalloproteinase-3. *Invest Ophthalmol Vis Sci* 49:2812-2822.
- Ju CR, Xia XZ and Chen RC. 2007. Expressions of tumor necrosis factor-converting enzyme and ErbB3 in rats with chronic obstructive pulmonary disease. *Chin Med J (Engl)* 120:1505-1510.
- Kalus I, Bormann U, Mzoughi M, Schachner M and Kleene R. 2006. Proteolytic cleavage of the neural cell adhesion molecule by ADAM17/TACE is involved in neurite outgrowth. *J Neurochem* 98:78-88.
- Karan D, Lin FC, Bryan M, Ringel J, Moniaux N, Lin MF and Batra SK. 2003. Expression of ADAMs (a disintegrin and metalloproteinases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. *Int J Oncol* 23:1365-1371.
- Karkkainen I, Rybnikova E, Pelto-Huikko M and Huovila AP. 2000. Metalloproteinase-disintegrin (ADAM) genes are widely and differentially expressed in the adult CNS. *Mol Cell Neurosci* 15:547-560.
- Kassiri Z, Oudit GY, Sanchez O, Dawood F, Mohammed FF, Nuttall RK, Edwards DR, Liu PP, Backx PH and Khokha R. 2005. Combination of tumor necrosis factor- $\alpha$  ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. *Circ Res* 97:380-390.
- Kassiri Z, Oudit GY, Kandalam V, Awad A, Wang X, Ziou X, Maeda N, Herzenberg AM and Scholey JW. 2009. Loss of TIMP3 enhances interstitial nephritis and fibrosis. *J Am Soc Nephrol* 20:1223-1235.
- Katakowski M, Chen J, Zhang ZG, Santra M, Wang Y and Chopp M. 2007. Stroke-induced subventricular zone proliferation is promoted by tumor necrosis factor- $\alpha$ -converting enzyme protease activity. *J Cereb Blood Flow Metab* 27:669-678.
- Katakowski M, Jiang F, Zheng X, Gutierrez JA, Szalad A and Chopp M. 2009. Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17. *Cancer Sci* 100:1597-1604.
- Kawaguchi N, Sundberg C, Kveiborg M, Moghadaszadeh B, Asmar M, Dietrich N, Thodeti CK, Nielsen FC, Moller P, Mercurio AM, Albrechtsen R and Wewer UM. 2003. ADAM12 induces actin

- cytoskeleton and extracellular matrix reorganization during early adipocyte differentiation by regulating beta1 integrin function. *J Cell Sci* 116:3893-3904.
- Kawaguchi M, Mitsuhashi Y and Kondo S. 2005. Overexpression of tumour necrosis factor-alpha-converting enzyme in psoriasis. *Br J Dermatol* 152:915-919.
- Kenny PA and Bissell MJ. 2007. Targeting TACE-dependent EGFR ligand shedding in breast cancer. *J Clin Invest* 117:337-345.
- Kermarrec N, Selloum S, Plantefeve G, Chosidow D, Paoletti X, Lopez A, Mantz J, Desmonts JM, Gougerot-Pocidalo MA and Chollet-Martin S. 2005. Regulation of peritoneal and systemic neutrophil-derived tumor necrosis factor-alpha release in patients with severe peritonitis: role of tumor necrosis factor-alpha converting enzyme cleavage. *Crit Care Med* 33:1359-1364.
- Kieseier BC, Pischel H, Neuen-Jacob E, Tourtellotte WW and Hartung HP. 2003. ADAM-10 and ADAM-17 in the inflamed human CNS. *Glia* 42:398-405.
- Kim ML, Zhang B, Mills IP, Milla ME, Brunden KR and Lee VM. 2008. Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. *J Neurosci* 28:12052-12061.
- Kini RM and Evans HJ. 1992. Structural domains in venom proteins: evidence that metalloproteinases and nonenzymatic platelet aggregation inhibitors (disintegrins) from snake venoms are derived by proteolysis from a common precursor. *Toxicon* 30:265-293.
- Koenen RR, Pruessmeyer J, Soehnlein O, Fraemohs L, Zernecke A, Schwarz N, Reiss K, Sarabi A, Lindbom L, Hackeng TM, Weber C and Ludwig A. 2009. Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. *Blood* 113:4799-4809.
- Kojro E and Fahrenholz F. 2005. The non-amyloidogenic pathway: structure and function of alpha-secretases. *Subcell Biochem* 38:105-127.
- Kojro E, Postina R, Buro C, Meiringer C, Gehrig-Burger K and Fahrenholz F. 2006. The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein. *FASEB J* 20:512-514.
- Kretschmar M, Doody J and Massague J. 1997. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. *Nature* 389:618-622.
- Kriegler M, Perez C, DeFay K, Albert I and Lu SD. 1988. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. *Cell* 53:45-53.
- Kuwahara I, Lillehoj EP, Koga T, Isohama Y, Miyata T and Kim KC. 2007. The signaling pathway involved in neutrophil elastase stimulated MUC1 transcription. *Am J Respir Cell Mol Biol* 37:691-698.
- Kwak HI, Mendoza EA and Bayless KJ. 2009. ADAM17 co-purifies with TIMP-3 and modulates endothelial invasion responses in three-dimensional collagen matrices. *Matrix Biol* 28:470-479.
- Lambert MH, Blackburn RK, Seaton TD, Kassel DB, Kinder DS, Leesnitzer MA, Bickett DM, Warner JR, Andersen MW, Badiang JG, Cowan DJ, Gaul MD, Petrov KG, Rabinowitz MH, Wiethe RW, Becherer JD, McDougald DL, Musso DL, Andrews RC and Moss ML. 2005. Substrate specificity and novel selective inhibitors of TNF-alpha converting enzyme (TACE) from two-dimensional substrate mapping. *Comb Chem High Throughput Screen* 8:327-339.
- Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C and Fahrenholz F. 1999. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. *Proc Natl Acad Sci USA* 96:3922-3927.
- Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G and Terzi F. 2005. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. *Nat Med* 11:867-874.
- Lee MH, Verma V, Maskos K, Becherer JD, Knauper V, Dodds P, Amour A and Murphy G. 2002. The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3. *FEBS Lett* 520:102-106.
- Leib SL, Clements JM, Lindberg RL, Heimgartner C, Loeffler JM, Pfister LA, Tauber MG and Leppert D. 2001. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. *Brain* 124:1734-1742.
- Leissring MA, Murphy MP, Mead TR, Akbari Y, Sugarman MC, Jannatipour M, Anliker B, Muller U, Saftig P, De Strooper B, Wolfe MS, Golde TE and LaFerla FM. 2002. A physiologic signaling role for the gamma-secretase-derived intracellular fragment of APP. *Proc Natl Acad Sci USA* 99:4697-4702.
- Lemjabbar H, Li D, Gallup M, Sidhu S, Drori E and Basbaum C. 2003. Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin. *J Biol Chem* 278:26202-26207.
- Leonard JD, Lin F and Milla ME. 2005. Chaperone-like properties of the prodomain of TNFalpha-converting enzyme (TACE) and the functional role of its cysteine switch. *Biochem J* 387:797-805.
- Lewis J. 1998. Notch signalling. A short cut to the nucleus. *Nature* 393:304-305.
- Li N, Boyd K, Dempsey PJ and Vignali DA. 2007. Non-cell autonomous expression of TNF-alpha-converting enzyme ADAM17 is required for normal lymphocyte development. *J Immunol* 178:4214-4221.
- Li X and Fan H. 2004. Loss of ectodomain shedding due to mutations in the metalloprotease and cysteine-rich/disintegrin domains of the tumor necrosis factor-alpha converting enzyme (TACE). *J Biol Chem* 279:27365-27375.
- Li X, Yan Y, Huang W, Yang Y, Wang H and Chang L. 2009. The regulation of TACE catalytic function by its prodomain. *Mol Biol Rep* 36:641-651.
- Li Z, Mei Y, Liu X and Zhou M. 2007. Neuregulin-1 only induces transphosphorylation between ErbB receptor heterodimer partners. *Cell Signal* 19:466-471.
- Lovering F and Zhang Y. 2005. Therapeutic potential of TACE inhibitors in stroke. *Curr Drug Targets CNS Neurol Disord* 4:161-168.
- Luetke NC, Qiu TH, Peiffer RL, Oliver P, Smithies O and Lee DC. 1993. TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. *Cell* 73:263-278.
- Luetke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A and Lee DC. 1999. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. *Development* 126:2739-2750.
- Madrigal JL, Hurtado O, Moro MA, Lizasoain I, Lorenzo P, Castrillo A, Bosca L and Leza JC. 2002. The increase in TNF-alpha levels is implicated in NF-kappaB activation and inducible nitric oxide synthase expression in brain cortex after immobilization stress. *Neuropsychopharmacology* 26:155-163.
- Mahmoodi M, Sahebjam S, Smookler D, Khokha R and Mort JS. 2005. Lack of tissue inhibitor of metalloproteinases-3 results in an enhanced inflammatory response in antigen-induced arthritis. *Am J Pathol* 166:1733-1740.
- Majka S, McGuire PG and Das A. 2002. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. *Invest Ophthalmol Vis Sci* 43:260-266.
- Mann GB, Fowler KJ, Gabriel A, Nice EC, Williams RL and Dunn AR. 1993. Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. *Cell* 73:249-261.
- Marcinkiewicz C. 2005. Functional characteristic of snake venom disintegrins: potential therapeutic implication. *Curr Pharm Des* 11:815-827.
- Marcinkiewicz C, Calvete JJ, Vijay-Kumar S, Marcinkiewicz MM, Raida M, Schick P, Lobb RR and Niewiarowski S. 1999. Structural and functional characterization of EMF10, a heterodimeric disintegrin from *Eristocophis macmahoni* venom that selectively inhibits alpha 5 beta 1 integrin. *Biochemistry* 38:13302-13309.
- Maretzky T, Schulte M, Ludwig A, Rose-John S, Blobel C, Hartmann D, Altevogt P, Saftig P and Reiss K. 2005. L1 is sequentially processed by two differently activated metalloproteinases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. *Mol Cell Biol* 25:9040-9053.
- Marin V, Montero-Julian F, Gres S, Bongrand P, Farnarier C and Kaplanski G. 2002. Chemotactic agents induce IL-6Ralpha shedding from polymorphonuclear cells: involvement of a



- metalloproteinase of the TNF- $\alpha$ -converting enzyme (TACE) type. *Eur J Immunol* 32:2965–2970.
- Martin EL, Moyer BZ, Pape MC, Starcher B, Leco KJ and Veldhuizen RA. 2003. Negative impact of tissue inhibitor of metalloproteinase-3 null mutation on lung structure and function in response to sepsis. *Am J Physiol Lung Cell Mol Physiol* 285:L1222–L1232.
- Maskos K, Fernandez-Catalan C, Huber R, Bourenkov GP, Bartunik H, Ellestad GA, Reddy P, Wolfson MF, Rauch CT, Castner BJ, Davis R, Clarke HR, Petersen M, Fitzner JN, Cerretti DP, March CJ, Paxton RJ, Black RA and Bode W. 1998. Crystal structure of the catalytic domain of human tumor necrosis factor- $\alpha$ -converting enzyme. *Proc Natl Acad Sci USA* 95:3408–3412.
- Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL and Beyreuther K. 1985. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci USA* 82:4245–4249.
- McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, Mansfield E, Gadina M, Karenko L, Pettersson T, McCarthy J, Frucht DM, Aringer M, Torosyan Y, Teppo AM, Wilson M, Karaarslan HM, Wan Y, Todd I, Wood G, Schlimgen R, Kumarajeewa TR, Cooper SM, Vella JP, Amos CI, Mulley J, Quane KA, Molloy MG, Ranki A, Powell RJ, Hitman GA, O'Shea JJ and Kastner DL. 1999. Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. *Cell* 97:133–144.
- McGeehan GM, Becherer JD, Bast RC, Jr, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, McElroy AB, Nichols J, Pryzwansky KM, Schoenen F, SekutL, Truesdale A, Verghese M, Warner J and Ways JP. 1994. Regulation of tumour necrosis factor- $\alpha$  processing by a metalloproteinase inhibitor. *Nature* 370:558–561.
- McGowan PM, Ryan BM, Hill AD, McDermott E, O'Higgins N and Duffy MJ. 2007. ADAM-17 expression in breast cancer correlates with variables of tumor progression. *Clin Cancer Res* 13:2335–2343.
- McGowan PM, McKiernan E, Bolster F, Ryan BM, Hill AD, McDermott EW, Evoy D, O'Higgins N, Crown J and Duffy MJ. 2008. ADAM-17 predicts adverse outcome in patients with breast cancer. *Ann Oncol* 19:1075–1081.
- Meli DN, Loeffler JM, Baumann P, Neumann U, Buhl T, Leppert D and Leib SL. 2004. In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF- $\alpha$  converting enzyme attenuates seizures and injury of the cerebral cortex. *J Neuroimmunol* 151:6–11.
- Menghini R, Menini S, Amoruso R, Fiorentino L, Casagrande V, Marzano V, Tornei F, Bertucci P, Iacobini C, Serino M, Porzio O, Hribal ML, Folli F, Khokha R, Urbani A, Lauro R, Pugliese G and Federici M. 2009. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. *Gastroenterology* 136:663–672 e4.
- Mercer B, Markland F and Minkin C. 1998. Contortrostatin, a homodimeric snake venom disintegrin, is a potent inhibitor of osteoclast attachment. *J Bone Miner Res* 13:409–414.
- Merchant NB, Rogers CM, Trivedi B, Morrow J and Coffey RJ. 2005. Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. *Surgery* 138:415–421.
- Merchant NB, Voskresensky I, Rogers CM, Lafleur B, Dempsey PJ, Graves-Deal R, Revetta F, Foutch AC, Rothenberg ML, Washington MK and Coffey RJ. 2008. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. *Clin Cancer Res* 14:1182–1191.
- Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA, Werb Z and Derynck R. 1995. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. *Nature* 376:337–341.
- Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremmel KE, Fung VP, Madani H and Widmer MB. 1993. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. *J Immunol* 151:1548–1561.
- Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawarna K, Kronheim SR, Petersen M, Gerhart M, Kozlosky CJ, March CJ and Black RA. 1994. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. *Nature* 370:218–220.
- Moriyama H, Tsukida T, Inoue Y, Yokota K, Yoshino K, Kondo H, Miura N and Nishimura S. 2004. Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. *J Med Chem* 47:1930–1938.
- Moss ML, Jin SL, Becherer JD, Bickett DM, Burkhart W, Chen WJ, Hassler D, Leesnitzer MT, McGeehan G, Milla M, Moyer M, Rocque W, Seaton T, Schoenen F, Warner J and Willard D. 1997a. Structural features and biochemical properties of TNF- $\alpha$  converting enzyme (TACE). *J Neuroimmunol* 72:127–129.
- Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Warner J, Willard D and Becherer JD. 1997b. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor- $\alpha$ . *Nature* 385:733–736.
- Moss ML, Bomar M, Liu Q, Sage H, Dempsey P, Lenhart PM, Gillispie PA, Stoeck A, Wildeboer D, Bartsch JW, Palmisano R and Zhou P. 2007. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. *J Biol Chem* 282:35712–35721.
- Moss ML, Sklair-Tavron L and Nudelman R. 2008. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. *Nat Clin Pract Rheumatol* 4:300–309.
- Murali R, Brennan PJ, Kieber-Emmons T and Greene MI. 1996. Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains. *Proc Natl Acad Sci USA* 93:6252–6257.
- Nakamura K, Iwamoto R and Mekada E. 1995. Membrane-anchored heparin-binding EGF-like growth factor (HB-EGF) and diphtheria toxin receptor-associated protein (DRAP27)/CD9 form a complex with integrin  $\alpha$ 3  $\beta$ 1 at cell-cell contact sites. *J Cell Biol* 129:1691–1705.
- Nakamura T, Abe H, Hirata A and Shimoda C. 2004. ADAM family protein Mde10 is essential for development of spore envelopes in the fission yeast *Schizosaccharomyces pombe*. *Eukaryot Cell* 3:27–39.
- Nanba D, Mammoto A, Hashimoto K and Higashiyama S. 2003. Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. *J Cell Biol* 163:489–502.
- Nath D, Slocombe PM, Stephens PE, Warn A, Hutchinson GR, Yamada KM, Docherty AJ and Murphy G. 1999. Interaction of metargidin (ADAM-15) with  $\alpha$ 5 $\beta$ 1 integrins on different haemopoietic cells. *J Cell Sci* 112:579–587.
- Nelson KK, Schlondorff J and Blobel CP. 1999. Evidence for an interaction of the metalloprotease-disintegrin tumour necrosis factor  $\alpha$  convertase (TACE) with mitotic arrest deficient 2 (MAD2), and of the metalloprotease-disintegrin MDC9 with a novel MAD2-related protein, MAD2beta. *Biochem J* 343:673–680.
- Nemo R, Murcia N and Dell KM. 2005. Transforming growth factor  $\alpha$  (TGF- $\alpha$ ) and other targets of tumor necrosis factor- $\alpha$  converting enzyme (TACE) in murine polycystic kidney disease. *Pediatr Res* 57:732–737.
- Newton RC and Decicco CP. 1999. Therapeutic potential and strategies for inhibiting tumor necrosis factor- $\alpha$ . *J Med Chem* 42:2295–2314.
- Nishi E, Hiraoka Y, Yoshida K, Okawa K and Kita T. 2006. Nardilysin enhances ectodomain shedding of heparin-binding epidermal growth factor-like growth factor through activation of tumor necrosis factor- $\alpha$ -converting enzyme. *J Biol Chem* 281:31164–31172.
- Oh ST, Schramme A, Stark A, Tilgen W, Gutwein P and Reichrath J. 2009. The disintegrin-metalloproteinases ADAM 10, 12 and 17 are upregulated in invading peripheral tumor cells of basal cell carcinomas. *J Cutan Pathol* 36:395–401.
- Ohta S, Harigai M, Tanaka M, Kawaguchi Y, Sugiura T, Takagi K, Fukasawa C, Hara M and Kamatani N. 2001. Tumor necrosis

- factor- $\alpha$  (TNF- $\alpha$ ) converting enzyme contributes to production of TNF- $\alpha$  in synovial tissues from patients with rheumatoid arthritis. *J Rheumatol* 28:1756-1763.
- Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, Suzuki H, Nakashima H, Eguchi K and Eguchi S. 2006. ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. *Arterioscler Thromb Vasc Biol* 26:e133-137.
- Olfa KZ, Jose L, Salma D, Amine B, Najet SA, Nicolas A, Maxime L, Raoudha Z, Kamel M, Jacques M, Jean-Marc S, Mohamed el A and Naziha M. 2005. Lebestatin, a disintegrin from *Macrovipera venom*, inhibits integrin-mediated cell adhesion, migration and angiogenesis. *Lab Invest* 85:1507-1516.
- Papadakis KA and Targan SR. 2000. Role of cytokines in the pathogenesis of inflammatory bowel disease. *Annu Rev Med* 51:289-298.
- Patel IR, Attur MG, Patel RN, Stuchin SA, Abagyan RA, Abramson SB and Amin AR. 1998. TNF- $\alpha$  convertase enzyme from human arthritis-affected cartilage: isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF- $\alpha$ . *J Immunol* 160:4570-4579.
- Peiretti F, Canault M, Deprez-Beauchair P, Berthet V, Bonardo B, Juhan-Vague I and Nalbone G. 2003a. Intracellular maturation and transport of tumor necrosis factor  $\alpha$  converting enzyme. *Exp Cell Res* 285:278-285.
- Peiretti F, Deprez-Beauchair P, Bonardo B, Aubert H, Juhan-Vague I and Nalbone G. 2003b. Identification of SAP97 as an intracellular binding partner of TACE. *J Cell Sci* 116:1949-1957.
- Peng Y, Lee DY, Jiang L, Ma Z, Schachter SC and Lemere CA. 2007. Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695. *Neuroscience* 150:386-395.
- Perez L, Kerrigan JE, Li X and Fan H. 2007. Substitution of methionine 435 with leucine, isoleucine, and serine in tumor necrosis factor  $\alpha$  converting enzyme inactivates ectodomain shedding activity. *Biochem Cell Biol* 85:141-149.
- Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ and Black RA. 1998. An essential role for ectodomain shedding in mammalian development. *Science* 282:1281-1284.
- Planque C, Kulasingan V, Smith CR, Reckamp K, Goodglick L and Diamandis EP. 2009. Identification of five candidate lung cancer biomarkers by proteomic analysis of conditioned media of four lung cancer cell lines. *Mol Cell Proteomics* 8:2746-2758.
- Plumb J, McQuaid S, Cross AK, Surr J, Haddock G, Bunning RA and Woodroffe MN. 2006. Upregulation of ADAM-17 expression in active lesions in multiple sclerosis. *Mult Scler* 12:375-385.
- Pradillo JM, Romera C, Hurtado O, Cardenas A, Moro MA, Leza JC, Davalos A, Castillo J, Lorenzo P and Lizasoain I. 2005. TNFR1 upregulation mediates tolerance after brain ischemic preconditioning. *J Cereb Blood Flow Metab* 25:193-203.
- Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C and Ullrich A. 1999. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. *Nature* 402:884-888.
- Qu D, Wang Y, Esmon NL and Esmon CT. 2007. Regulated endothelial protein C receptor shedding is mediated by tumor necrosis factor- $\alpha$  converting enzyme/ADAM17. *J Thromb Haemost* 5:395-402.
- Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL and Rizzolio MC. 2001. Design of selective and soluble inhibitors of tumor necrosis factor- $\alpha$  converting enzyme (TACE). *J Med Chem* 44:4252-4267.
- Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, Shows D, Peschon JJ and Black RA. 2000. Functional analysis of the domain structure of tumor necrosis factor- $\alpha$  converting enzyme. *J Biol Chem* 275:14608-14614.
- Reddy AB, Ramana KV, Srivastava S, Bhatnagar A and Srivastava SK. 2009. Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)- $\alpha$  via protein kinase C- $\delta$  and TNF- $\alpha$  converting enzyme in vascular smooth muscle cells. *Endocrinology* 150:63-74.
- Reiss K and Saftig P. 2009. The "a disintegrin and metalloprotease" (ADAM) family of sheddases: physiological and cellular functions. *Semin Cell Dev Biol* 20:126-137.
- Richards WG, Sweeney WE, Yoder BK, Wilkinson JE, Woychik RP and Avner ED. 1998. Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. *J Clin Invest* 101:935-939.
- Robertshaw HJ and Brennan FM. 2005. Release of tumour necrosis factor  $\alpha$  (TNF $\alpha$ ) by TNF $\alpha$  cleaving enzyme (TACE) in response to septic stimuli in vitro. *Br J Anaesth* 94:222-228.
- Romera C, Hurtado O, Botella SH, Lizasoain I, Cardenas A, Fernandez-Tome P, Leza JC, Lorenzo P and Moro MA. 2004. In vitro ischemic tolerance involves upregulation of glutamate transport partly mediated by the TACE/ADAM17-tumor necrosis factor- $\alpha$  pathway. *J Neurosci* 24:1350-1357.
- Rovida E, Paccagnini A, Del Rosso M, Peschon J and Dello Sbarba P. 2001. TNF- $\alpha$ -converting enzyme cleaves the macrophage colony-stimulating factor receptor in macrophages undergoing activation. *J Immunol* 166:1583-1589.
- Rubio-Araiz A, Arevalo-Martin A, Gomez-Torres O, Navarro-Galve B, Garcia-Ovejero D, Suetterlin P, Sanchez-Heras E, Molina-Holgado E and Molina-Holgado F. 2008. The endocannabinoid system modulates a transient TNF pathway that induces neural stem cell proliferation. *Mol Cell Neurosci* 38:374-380.
- Ruchatz H, Leung BP, Wei XQ, McInnes IB and Liew FY. 1998. Soluble IL-15 receptor  $\alpha$ -chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. *J Immunol* 160:5654-5660.
- Rundhaug JE. 2005. Matrix metalloproteinases and angiogenesis. *J Cell Mol Med* 9:267-285.
- Sahebjam S, Khokha R and Mort JS. 2007. Increased collagen and aggrecan degradation with age in the joints of Timp3(-/-) mice. *Arthritis Rheum* 56:905-909.
- Sanderson MP, Abbott CA, Tada H, Seno M, Dempsey PJ and Dunbar AJ. 2006. Hydrogen peroxide and endothelin-1 are novel activators of betacellulin ectodomain shedding. *J Cell Biochem* 99:609-623.
- Sastre M, Walter J and Gentleman SM. 2008. Interactions between APP secretases and inflammatory mediators. *J Neuroinflammation* 5:25.
- Satoh M, Nakamura M, Satoh H, Saitoh H, Segawa I and Hiramori K. 2000. Expression of tumor necrosis factor- $\alpha$ -converting enzyme and tumor necrosis factor- $\alpha$  in human myocarditis. *J Am Coll Cardiol* 36:1288-1294.
- Satoh M, Iwasaka J, Nakamura M, Akatsu T, Shimoda Y and Hiramori K. 2004. Increased expression of tumor necrosis factor- $\alpha$  converting enzyme and tumor necrosis factor- $\alpha$  in peripheral blood mononuclear cells in patients with advanced congestive heart failure. *Eur J Heart Fail* 6:869-875.
- Satoh M, Ishikawa Y, Itoh T, Minami Y, Takahashi Y and Nakamura M. 2008. The expression of TNF- $\alpha$  converting enzyme at the site of ruptured plaques in patients with acute myocardial infarction. *Eur J Clin Invest* 38:97-105.
- Schafer B, Marg B, Gschwind A and Ullrich A. 2004. Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. *J Biol Chem* 279:47929-47938.
- Schaff U, Mattila PE, Simon SI and Walcheck B. 2008. Neutrophil adhesion to E-selectin under shear promotes the redistribution and co-clustering of ADAM17 and its proteolytic substrate L-selectin. *J Leukoc Biol* 83:99-105.
- Schlondorff J and Blobel CP. 1999. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. *J Cell Sci* 112:3603-3617.
- Schlondorff J, Becherer JD and Blobel CP. 2000. Intracellular maturation and localization of the tumour necrosis factor  $\alpha$  convertase (TACE). *Biochem J* 347:131-138.
- Schmitmeier S, Markland FS, Ritter MR, Sawcer DE and Chen TC. 2003. Functional effect of conortrostatin, a snake venom disintegrin,

- on human glioma cell invasion in vitro. *Cell Commun Adhes* 10:1-16.
- Schramme A, Abdel-Bakky MS, Kampf-Kolb N, Pfeilschifter J and Gutwein P. 2008. The role of CXCL16 and its processing metalloproteinases ADAM10 and ADAM17 in the proliferation and migration of human mesangial cells. *Biochem Biophys Res Commun* 370:311-316.
- Schroeter EH, Kisslinger JA and Kopan R. 1998. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. *Nature* 393:382-386.
- Seifert T, Kieseier BC, Ropele S, Strasser-Fuchs S, Quehenberger F, Fazekas F and Hartung HP. 2002. TACE mRNA expression in peripheral mononuclear cells precedes new lesions on MRI in multiple sclerosis. *Mult Scler* 8:447-451.
- Serino M, Menghini R, Fiorentino L, Amoruso R, Mauriello A, Lauro D, Sbraccia P, Hribal ML, Lauro R and Federici M. 2007. Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. *Diabetes* 56:2541-2546.
- Serwin AB, Sokolowska M and Chodyncka B. 2007. Tumour necrosis factor alpha (TNF-alpha)-converting enzyme (TACE) and soluble TNF-alpha receptor type 1 in psoriasis patients treated with narrowband ultraviolet B. *Photodermatol Photoimmunol Photomed* 23:130-134.
- Shah BH and Catt KJ. 2006. TACE-dependent EGF receptor activation in angiotensin-II-induced kidney disease. *Trends Pharmacol Sci* 27:235-237.
- Shi W, Chen H, Sun J, Buckley S, Zhao J, Anderson KD, Williams RG and Warburton D. 2003. TACE is required for fetal murine cardiac development and modeling. *Dev Biol* 261:371-380.
- Shimoda Y, Satoh M, Nakamura M, Akatsu T and Hiramori K. 2005. Activated tumour necrosis factor-alpha shedding process is associated with in-hospital complication in patients with acute myocardial infarction. *Clin Sci (Lond)* 108:339-347.
- Sibilia M and Wagner EF. 1995. Strain-dependent epithelial defects in mice lacking the EGF receptor. *Science* 269:234-238.
- Singh RJ, Mason JC, Lidington EA, Edwards DR, Nuttall RK, Khokha R, Knauper V, Murphy G and Gavrilovic J. 2005. Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. *Cardiovasc Res* 67:39-49.
- Six E, Ndiaye D, Laabi Y, Brou C, Gupta-Rossi N, Israel A and Logeat F. 2003. The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and gamma-secretase. *Proc Natl Acad Sci USA* 100:7638-7643.
- Skovronsky DM, Fath S, Lee VM and Milla ME. 2001. Neuronal localization of the TNFalpha converting enzyme (TACE) in brain tissue and its correlation to amyloid plaques. *J Neurobiol* 49:40-46.
- Smith KM, Gaultier A, Cousin H, Alfandari D, White JM and DeSimone DW. 2002. The cysteine-rich domain regulates ADAM protease function in vivo. *J Cell Biol* 159:893-902.
- Smookler DS, Mohammed FF, Kassiri Z, Duncan GS, Mak TW and Khokha R. 2006. Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. *J Immunol* 176:721-725.
- Solomon A, Akabayov B, Frenkel A, Milla ME and Sagi I. 2007. Key feature of the catalytic cycle of TNF-alpha converting enzyme involves communication between distal protein sites and the enzyme catalytic core. *Proc Natl Acad Sci USA* 104:4931-4936.
- Song D, Ye X, Xu H and Liu SF. 2009. Activation of endothelial intrinsic NF-kB pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic mice. *Blood* 114:2521-2529.
- Soond SM, Everson B, Riches DW and Murphy G. 2005. ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking. *J Cell Sci* 118:2371-2380.
- Spertini O, Luscinskas FW, Gimbrone MA, Jr and Tedder TF. 1992. Monocyte attachment to activated human vascular endothelium in vitro is mediated by leukocyte adhesion molecule-1 (L-selectin) under nonstatic conditions. *J Exp Med* 175:1789-1792.
- Surena AL, de Faria GP, Studler JM, Peiretti F, Pidoux M, Camonis J, Chneiweiss H, Formstecher E and Junier MP. 2009. DLG1/SAP97 modulates transforming growth factor alpha bioavailability. *Biochim Biophys Acta* 1793:264-272.
- Swendeman S, Mendelson K, Weskamp G, Horiuchi K, Deutsch U, Scherle P, Hooper A, Rafii S and Blobel CP. 2008. VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. *Circ Res* 103:916-918.
- Tachida Y, Nakagawa K, Saito T, Saido TC, Honda T, Saito Y, Murayama S, Endo T, Sakaguchi G, Kato A, Kitazume S and Hashimoto Y. 2008. Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production. *J Neurochem* 104:1387-1393.
- Takamune Y, Ikebe T, Nagano O and Shinohara M. 2008. Involvement of NF-kappaB-mediated maturation of ADAM-17 in the invasion of oral squamous cell carcinoma. *Biochem Biophys Res Commun* 365:393-398.
- Tanabe Y, Kasahara T, Momoi T and Fujita E. 2008. Neuronal RA175/SynCAM1 isoforms are processed by tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM17-like proteases. *Neurosci Lett* 444:16-21.
- Tanahashi H and Yoshioka K. 2008. RNA interference silencing of DRAL affects processing of amyloid precursor protein. *Neurosci Lett* 439:293-297.
- Tanaka M, Namba D, Mori S, Shiba F, Ishiguro H, Yoshino K, Matsuura N and Higashiyama S. 2004. ADAM binding protein Eve-1 is required for ectodomain shedding of epidermal growth factor receptor ligands. *J Biol Chem* 279:41950-41959.
- Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekada E and Nakano H. 2005. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. *Clin Cancer Res* 11:4783-4792.
- Tellier E, Canault M, Rebsomen L, Bonardo B, Juhan-Vague I, Nalbone G and Peiretti F. 2006. The shedding activity of ADAM17 is sequestered in lipid rafts. *Exp Cell Res* 312:3969-3980.
- Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC, Barnard JA, Yuspa SH, R. J. Coffey RJ and Magnuson T. 1995. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. *Science* 269:230-234.
- Togashi N, Ura N, Higashiura K, Murakami H and Shimamoto K. 2002. Effect of TNF-alpha-converting enzyme inhibitor on insulin resistance in fructose-fed rats. *Hypertension* 39:578-580.
- Toussey T, Thathiah A, Jorissen E, Raemaekers T, Konietzko U, Reiss K, Maes E, Snellinx A, Serneels L, Nyabi O, Annaert W, Saftig P, Hartmann D and De Strooper B. 2009. ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase. *J Biol Chem* 284:11738-11747.
- Trifilieff A, Walker C, Keller T, Kottirsch G and Neumann U. 2002. Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation. *Br J Pharmacol* 135:1655-1664.
- Trikha M, De Clerck YA and Markland FS. 1994. Contortrostatin, a snake venom disintegrin, inhibits beta 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. *Cancer Res* 54:4993-4998.
- Tsai TJ, Sheu JR, Chen YM, Yen CJ, Chen CF and Huang TF. 1995. Disintegrin modulates rat glomerular mesangial cell behavior. *Nephron* 70:83-90.
- Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, Hsu MT, Hsiao M, Huang HD and Tsou AP. 2009. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. *Hepatology* 49:1571-1582.
- Tsakadze NL, Sithu SD, Sen U, English WR, Murphy G and D'Souza SE. 2006. Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). *J Biol Chem* 281:3157-3164.
- Tselepis VH, Green LJ and Humphries MJ. 1997. An RGD to LDV motif conversion within the disintegrin kistrin generates an integrin antagonist that retains potency but exhibits altered receptor specificity. Evidence for a functional equivalence of acidic integrin-binding motifs. *J Biol Chem* 272:21341-21348.



- Tsuji F, Oki K, Okahara A, Suhara H, Yamanouchi T, Sasano M, Mita S and Horiuchi M. 2002. Differential effects between marimastat, a TNF- $\alpha$  converting enzyme inhibitor, and anti-TNF- $\alpha$  antibody on murine models for sepsis and arthritis. *Cytokine* 17:294–300.
- Uchiyama-Tanaka Y, Matsubara H, Nozawa Y, Murasawa S, Mori Y, Kosaki A, Maruyama K, Masaki H, Shibasaki Y, Fujiyama S, Nose A, Iba O, Hasagawa T, Tateishi E, Higashiyama S and Iwasaka T. 2001. Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells. *Kidney Int* 60:2153–2163.
- Utsugi T, Ohno T, Ohyama Y, Uchiyama T, Saito Y, Matsumura Y, Aizawa H, Itoh H, Kurabayashi M, Kawazu S, Tomono S, Oka Y, Suga T, Kuro-o M, Nabeshima Y and Nagai R. 2000. Decreased insulin production and increased insulin sensitivity in the klothe mutant mouse, a novel animal model for human aging. *Metabolism* 49:1118–1123.
- Venkatesan AM, Davis JM, Grosu GT, Baker J, Zask A, Levin JJ, Ellingboe J, Skotnicki JS, DiJoseph JE, Sung A, Jin G, Xu W, McCarthy DJ and Barone D. 2004. Synthesis and structure-activity relationships of 4-alkynylphenoxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor- $\alpha$  converting enzyme and matrix metalloproteinase inhibitors. *J Med Chem* 47:6255–6269.
- Walker EJ and Rosenberg GA. 2009. TIMP-3 and MMP-3 contribute to delayed inflammation and hippocampal neuronal death following global ischemia. *Exp Neurol* 216:122–131.
- Wang J, Al-Lamki RS, Zhang H, Kirkiles-Smith N, Gaeta ML, Thiru S, Pober JS and Bradley JR. 2003. Histamine antagonizes tumor necrosis factor (TNF) signaling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool. *J Biol Chem* 278:21751–21760.
- Wang X, He K, Gerhart M, Huang Y, Jiang J, Paxton RJ, Yang S, Lu C, Menon RK, Black RA, Baumann G and Frank SJ. 2002. Metalloprotease-mediated GH receptor proteolysis and GHBP shedding. Determination of extracellular domain stem region cleavage site. *J Biol Chem* 277:50510–50519.
- Wang X, Feuerstein GZ, Xu L, Wang H, Schumacher WA, Ogletree ML, Taub R, Duan JJ, Decicco CP and Liu RQ. 2004. Inhibition of tumor necrosis factor- $\alpha$ -converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. *Mol Pharmacol* 65:890–896.
- Wang X, Jiang J, Warram J, Baumann G, Gan Y, Menon RK, Denson LA, Zinn KR and Frank SJ. 2008. Endotoxin-induced proteolytic reduction in hepatic growth hormone (GH) receptor: a novel mechanism for GH insensitivity. *Mol Endocrinol* 22:1427–1437.
- Wang X, Oka T, Chow FL, Cooper SB, Odenbach J, Lopaschuk GD, Kassiri Z and Fernandez-Patron C. 2009. Tumor necrosis factor- $\alpha$ -converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. *Hypertension* 54:575–582.
- Wang Y, Herrera AH, Li Y, Belani KK and Walcheck B. 2009. Regulation of mature ADAM17 by redox agents for L-selectin shedding. *J Immunol* 182:2449–2457.
- Weinger JG, Omari KM, Marsden K, Raine CS and Shafit-Zagardo B. 2009. Up-regulation of soluble Axl and Mer receptor tyrosine kinases negatively correlates with Gas6 in established multiple sclerosis lesions. *Am J Pathol* 175:283–293.
- Wewer UM, Morgelin M, Holck P, Jacobsen J, Lydolph MC, Johnsen AH, Kveiborg M and Albrechtsen R. 2006. ADAM12 is a four-leafed clover: the excised prodomain remains bound to the mature enzyme. *J Biol Chem* 281:9418–9422.
- Wiley HS, Woolf MF, Opresko LK, Burke PM, Will B, Morgan JR and Lauffenburger DA. 1998. Removal of the membrane-anchoring domain of epidermal growth factor leads to intracrine signaling and disruption of mammary epithelial cell organization. *J Cell Biol* 143:1317–1328.
- Wisniewska M, Goettig P, Maskos K, Belouski E, Winters D, Hecht R, Black R and Bode W. 2008. Structural determinants of the ADAM inhibition by TIMP-3: crystal structure of the TACE-N-TIMP-3 complex. *J Mol Biol* 381:1307–1319.
- Wolfe MS, De Los Angeles J, Miller DD, Xia W and Selkoe DJ. 1999. Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease. *Biochemistry* 38:11223–11230.
- Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR and Decicco CP. 2001. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor  $\alpha$  release in vitro and in vivo. *J Med Chem* 44:2636–2660.
- Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL and Gurney ME. 1999. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. *Nature* 402:533–537.
- Yasuda H, Hirata S, Inoue K, Mashima H, Ohnishi H and Yoshida M. 2007. Involvement of membrane-type bile acid receptor M-BAR/ TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. *Biochem Biophys Res Commun* 354:154–159.
- Yeh CH, Peng HC, Yang RS and Huang TF. 2001. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective  $\alpha(v)\beta(3)$  blockade of endothelial cells. *Mol Pharmacol* 59:1333–1342.
- Yin J and Yu FS. 2009. ERK1/2 mediate wounding- and G-protein-coupled receptor ligands-induced EGFR activation via regulating ADAM17 and HB-EGF shedding. *Invest Ophthalmol Vis Sci* 50:132–139.
- Yoshimura T, Tomita T, Dixon MF, Axon AT, Robinson PA and Crabtree JE. 2002. ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in *Helicobacter pylori*-infected, normal, and neoplastic gastric mucosa. *J Infect Dis* 185:332–340.
- Zhang Q, Thomas SM, Lui VW, Xi S, Siegfried JM, Fan H, Smithgall TE, Mills GB and Grandis JR. 2006. Phosphorylation of TNF- $\alpha$  converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. *Proc Natl Acad Sci USA* 103:6901–6906.
- Zhao J, Chen H, Peschon JJ, Shi W, Zhang Y, Frank SJ and Warburton D. 2001. Pulmonary hypoplasia in mice lacking tumor necrosis factor- $\alpha$  converting enzyme indicates an indispensable role for cell surface protein shedding during embryonic lung branching morphogenesis. *Dev Biol* 232:204–218.
- Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE and Chopp M. 2009. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. *Cancer Biol Ther* 8:1045–1054.
- Zheng Y, Schlondorff J and Blobel CP. 2002. Evidence for regulation of the tumor necrosis factor  $\alpha$ -convertase (TACE) by protein-tyrosine phosphatase PTPH1. *J Biol Chem* 277:42463–42470.
- Zhou Q, Nakada MT, Brooks PC, Swenson SD, Ritter MR, Argounova S, Arnold C and Markland FS. 2000. Contortrostatin, a homodimeric disintegrin, binds to integrin  $\alpha v \beta 5$ . *Biochem Biophys Res Commun* 267:350–355.

Editor: Michael M. Cox